Yearbook 2012 - Galderma

committed 

we are 

yearbook 2 0 1 2

Galderma 

2012 

CONTINUE THE EXPERIENCE ONLINE 

Get access to the enriched online edition of the yearbook at yearbook.galderma.com, 

or by scanning the QR codes present in every chapter. 

GALDERMA CORPORATE SERVICES - Tour Europlaza - 20, Avenue André Prothin - 92927 La Défense Cedex – France. www.galderma.com. This document has been prepared by the Corporate 

& Digital Communications Department. 

Executive director: Humberto C. Antunes - Executive editor: Sébastien Cros - Senior editor: Nadège des Closets - Design and production: 

. June 2013. Photos: Kim 

Freeman, Tom Hussey Photography, LLC, Gavin Jowitt/Capa Pictures, Michel Labelle, Yannick Labrousse, Yann Leborgne, Mats Lundqvist, Nathalie Oundjian-Guréghian, Corbis, Plainpicture, 

iStock, BSIP, Phanie, Getty Images, Thinkstock, Galderma, R.R. - Epiduo, Oracea, Clobex, Differin, Rozex/MetroGel, Silkis/Vectical, Benzac, Tri-Luma, Loceryl, Cetaphil, Metvix, Azzalure, 

Restylane and Emervel are registered trademarks of Galderma. Dysport is a trademark of Ipsen.

CONTENTS 

INTERVIEW WITH HUMBERTO C. ANTUNES 

EXECUTIVE COMMITTEE 

2012 KEY FACTS 

2012 KEY FIGURES 

PAGE 06 

PAGE 08 

PAGE 10 

PAGE 12 

We are committed to delivering 

PAGES 14 TO 21 


innovative medical solutions to meet 


the dermatological needs of people 

throughout their lifetime while 


serving healthcare professionals 

around the world. 


04 

05

Doing the 

right thing 

every day 

What is the driving force behind 

Galderma’s ambition statement 

We want to provide the best medical solutions in dermatology. 

That is what Galderma stands for. But how 

we do business is just as important as the products and 

services we offer. Galderma has evolved from a mainly 

prescription medication company to one that also offers 

Aesthetic & Corrective solutions and Self-medication 

drugs. Our Prescription business has thrived in ways 

that were unimaginable before. As we developed these 

businesses, we realized that each had a specific model. 

We also examined how people - patients, healthcare 

professionals, stakeholders and regulators - interacted 

with the company. Now, we see the future differently. 

How does this statement 

reflect changes in the company 

and its environment 

We are at a turning point, due to demographic evolution, 

the distribution of wealth in new markets and increased 

social mobility. Access to better, more innovative products 

is improving. Communications have changed, so 

have regulations. Our new ambition statement stems 

from our fundamental objective to provide innovative 

medical solutions for people with skin, hair and nail needs. 

Our model is based on research and development and 

evidence-based treatments. It is a medical business, and 

we are focusing on solutions, not just drugs. We meet 

patients’ needs through the convergence of science and 

technology: chemistry, physics, devices, and even light. 

As we are providing solutions for people with medical 

needs in dermatology, we are working more closely with 

healthcare professionals, who are in the best position to 

diagnose a problem and prescribe the right solution. 

Are you broadening your audience 

Providing the right solutions is not simply about inventing 

them. We have to make them accessible. The 

world has become very complex. Developing a breakthrough 

drug does not necessarily mean it will become 

accessible. It requires regulatory approval and listing 

in patients’ formularies. Insurance companies need 

to recognize its value and agree to pay for it. Pharmacies, 

hospitals or clinics need to carry it. We must work 

with all these partners to ensure the availability of our 

products and treatments. Patients are becoming more 

demanding too: they want solutions immediately - and 

they deserve to get them! 

The world’s one million dermatology-related healthcare 

providers have a huge impact. We will talk to them. 

Hundreds of thousands of pharmacists carry our products. 

We are registering products in more places and 

reaching new cities in countries where we have sometimes 

been for a long time. We are launching products, 

of course, but the biggest change is our role as a catalyst. 

It will energize us to go the extra mile and ensure that 

anybody who needs to, can have access to Galderma’s 

medical solutions. 

Why was the company reorganized 

into three Global Business Units 

We restructured into business units that work together, 

transversally. Why Because the solutions people need 

do not just come from standalone Prescriptions, Selfmedication 

or Aesthetic & Corrective treatments, but 

from a combination of all of these. We offer solutions 

through a transversal, holistic approach to treatment. 

A skin cancer patient, for example, needs a selfmedication 

solution that helps prevent sun damage, he/ 

she also needs prescription drugs to treat the lesions 

and procedures that will correct or restore part of the 

damage. Today, Galderma offers all three of these solutions. 

We have the same approach for milder afflictions. 

Galderma's strategy is to be a 

'lifetime' brand: what is behind this 

approach 

Healthy skin is a very precious asset throughout our 

entire life, and people are becoming increasingly 

aware of this. The world's population is ageing, not just 

in Europe but also in countries like Brazil or China. 

As we live longer, we aspire to a better quality of life. 

Galderma’s approach is very positive and optimistic: 

supporting people take care of their skin and appearance 

helps them to live a longer, happier life. 

We are focusing 

on solutions, 

not just drugs. 

Galderma’s culture is founded on 

ethical values: how does that influence 

your business 

Dermatology is fascinating. It is medical, so it has an 

impact on the body. However in aesthetic dermatology, 

you can also change lives by having an impact on the 

soul and spirit. At Galderma, we have a mission, a vision 

and an ambition. We wish to serve people throughout 

the whole of their lifetime, so the way in which we 

do that is extremely important. The sustainability of 

our business and our mission depends on doing things 

right, every day. Respecting the rules, of course, but 

also answering needs and building on the responsible 

principles we share. In the digital age, it is important to 

train all our teams to communicate effectively with physicians 

and patients, to know the rules and regulations. 

It is about interaction with the outside world but also 

how we proceed internally, how Galderma respects the 

environment and diversity. We are committed. 

HUMBERTO C. ANTUNES 

PRESIDENT & CEO 

06 

07

Executive 

Committee 

JANUSZ CZERNIELEWSKI 

VICE-PRESIDENT 

MEDICAL AFFAIRS 

ALAIN JACOT 


SCIENTIFIC DIVISION 

LYDIE FRÈRE 

GENERAL COUNSEL 

ALBERT DRAAIJER 

VICE-PRESIDENT BUSINESS 

DEVELOPMENT & MARKETS, 


SELF-MEDICATION GLOBAL 

BUSINESS UNIT, 

VICE-PRESIDENT A&C 

GLOBAL BUSINESS UNIT 

ALAIN KIRSCH 

VICE-PRESIDENT HUMAN 

RESOURCES 

CÉCILE DUSSART 


MANUFACTURING 

& TECHNICAL OPERATIONS 

HUMBERTO C. ANTUNES 

PRESIDENT & CHIEF 

EXECUTIVE OFFICER 

CHRISTIAN MATTON 


CORPORATE GENERAL 

COUNSEL 

VIVIANE MONGES 

VICE-PRESIDENT FINANCE 

& ADMINISTRATION & CFO 

FRANÇOIS FOURNIER 


NORTH AMERICA 

& PRESIDENT USA, 


PRESCRIPTION GLOBAL 

BUSINESS UNIT 

08 

09

Key facts 


A NEW ORGANIZATION, A NEW AMBITION STATEMENT, 

NUMEROUS PRODUCT LAUNCHES AND THE 

CONTINUED INTERNATIONAL EXPANSION: 

2012 IMPROVED GALDERMA'S LEADERSHIP 

IN THE FIELD OF DERMATOLOGY. 

"AMBITION 

STATEMENT" 

In June 2012, Galderma confirmed 

its commitment to delivering medical 

solutions to patients, consumers 

and healthcare professionals, with a new 

ambition statement. 

No. 

1 

EPIDUO 

has been the 

No. 1 prescribed 

branded 

topical agent 

used in the acne 

therapeutic 

field in 

the World 

since 2011 (1) . 

New office in Shanghai 

At the end of 2012, Galderma China (2) inaugurated 

its new office facilities in Shanghai, which have become 

the headquarters for the Greater China region. 

92% 

participation rate for 

the first global employee 

survey, showing how 

willing Galderma people 

are to contribute to 

the company’s evolution. 

3 

Global Business Units 

Galderma is implementing 

a new organization to 

better serve its 3 markets: 

Prescription, Self-medication 

and Aesthetic & Corrective. 

Rosacea 

campaign 

The “U.S. Face-to-Face with Rosacea” 

campaign features Cynthia Nixon, 

actress in Sex and the City, who was 

herself diagnosed with rosacea. The 

campaign aims at changing the way 

people view rosacea, to help improve 

patients’ quality of life. 

www.rosaceafacts.com 

New territories 

for Dysport 

Ipsen and Galderma increased their 

collaboration for Dysport, one of 

the leaders in the aesthetic muscle relaxant 

market. Both companies renewed their 

partnership in Brazil and Argentina, and 

extended it to Australia and South Korea. 

Restylane 

Skinboosters 

After launching a campaign combining 

outdoor, print, digital and PR 

communications with an in-clinic 

campaign in Sweden and Mexico. 

Restylane Skinboosters sales rose by 

more than 60% in the two test countries 

during the project period. 

Launch of 

Cetaphil 

Dermacontrol 

a cosmetic range designed for use in 

patients treated for acne. The Cetaphil 

range has offered patients cleansing and 

moisturizing skincare solutions for over 

60 years. Today, it includes 16 products. 

1,500 

attendees at the two 

Galderma symposia for 

acne and rosacea during the 

European Academy 

of Dermatology and 

Venereology (EADV) in Prague. 

12 

DECEMBER 

Galderma 

and Spirig 

(1) Source: IMS Health - Monthly Midas database, 

all countries selected - Topical anti acne market - Nov. 2012 MAT, 

retail Rx Market - at sales manufacturerlocal currency dollar value. 

(2) Under the Q-Med legal entity. 

entered into a definitive agreement under 

which Galderma will acquire Spirig, the 

leader in dermatology in Switzerland. 

300 patients 

have been enrolled in the phase II 

clinical study of NVC-422 

for Impetigo. This formulation, 

developed by a Galderma and 

NovaBay R&D partnership, could 

replace traditional antibiotics 

in the treatment of Impetigo. 

10 

11

Key figures 


FIVE YEARS OF GROWTH HAVE TURNED 

GALDERMA INTO A COMPANY OPERATING 

WORLDWIDE, WITH A BALANCED 

PORTFOLIO OF MEDICAL SOLUTIONS 

AND BRANDS IN DERMATOLOGY. 

SALES BY FRANCHISE 

in million Euros 

Acne 356.1 

Therapeutic Skincare Line 290.6 

Rosacea 287.3 

Aesthetic & Corrective 268.6 

Psoriasis 117.4 

Onychomycosis 103.7 

Skin Cancer 23.2 

Pigmentary Disorders 5.1 

Other Products 138.9 

GENDER DISTRIBUTION 

53 % 47 % 

The company has wholly-owned affiliates in 31 countries 

with a worldwide network of exclusive distributors and employs 

more than 4,200 people around the world. 

SALES BY GEOGRAPHIC AREA 

SALES BY BUSINESS LINES 

Galderma's overall growth rate in 2012 

versus 2011 went up 5.9% like-for-like 

and 12.9% based on reported figures. 

Galderma made the most of 

2012 by redefining its ambition 

statement, striking the right balance 

in its growth drivers and continuing 

its international expansion. 

20 % 

27 % 

53 % 

AESTHETIC & 

CORRECTIVE 

SELF-MEDICATION 

PRESCRIPTION 

2012 sales 

€1.59 Billion 

GROWTH OVER FIVE YEARS 

in million Euros - Sales more than doubled in five years. 

1,600 

1,400 

1,200 

1,000 

800 

600 

400 

735 

2007 

854 

978 

1,203 

1,410 

1,591 

2008 2009 2010 2011 2012 

Source: Company data at the end of December 2012 - At published rates. 

North America 49% 

8 19% 57 12 

Galderma conducts research 

in 8 key therapeutic areas. 

Latin America 12% 

of sales are invested to 

discover and develop 

new products and access 

innovative technologies. 

EMEA 24% 

new patents registered in 2012. 

6,500 patent applications and 

patents have been filed by 

Galderma since its creation. 

Asia Pacific 15% 

new chemical entities in 

development and 7 products 

tested in Phase II and Phase III 

clinical studies. 

12 

13

FOCUSED 

FRANÇOIS FOURNIER 


OF THE PRESCRIPTION 

GLOBAL BUSINESS UNIT 

ALBERT DRAAIJER AND FRANÇOIS 

FOURNIER DISCUSS HOW 

GALDERMA IS GEARING UP TO 

FACE NEW OPPORTUNITIES. 

What is the aim of the new organization 

François Fournier: We have exciting opportunities 

ahead of us. Our new organization in Global Business 

Units empowers us to achieve our ambitions in the 

Prescription, Self-medication and Aesthetic & 

Corrective businesses simultaneously. It will enable 

us to embrace market diversity, from a changing 

landscape in the U.S., to new needs in Europe and 

opportunities in the fastest growing economies. 

Albert Draaijer: We are experiencing a global spread 

of interest for dermatology with increasing demand 

for new products and solutions. Latin America and 

Asia are growing fast. The new organization is going 

to allow us to leverage and accelerate the development 

of each of our three businesses. 

How does this change translate 

Galderma’s ambitions 

AD: We have put the triple business model in place. As 

a result, almost every country has a Prescription team, 

a Self-medication team and an Aesthetic & Corrective 

team. With the help of the functions represented in the 

GBUs, we have been very successful in opening new 

fields of dermatology in various countries. 

FF: We are rolling out our extended portfolio 

geographically, with more global products for greater 

impact and alignment. We work closely with the 

markets so that we can adjust to local specificities. 

We are 

committed... 

How do you see the future 

FF: People will remain at the heart of our actions. 

Dermatology is a specialty with a strong human 

component. We think about patients first, providing 

them with effective and safe solutions. We will 

strengthen our partnerships with dermatology 

organizations and our long-established relationships 

with healthcare professionals. With a lifetime portfolio, 

three businesses, global reach and reinforced 

competitiveness, our future is bright. 

AD: Galderma was a very young company 10 years 

ago. We were well established in the US, with a 

smaller presence in other parts of the world. Today, 

we have a sound geographic balance, with a presence 

in more than 70 countries. We are poised for growth 

because we are rolling out to the whole world and 

strengthening our leadership in dermatology. 

ALBERT DRAAIJER 

VICE-PRESIDENT OF THE 

SELF-MEDICATION AND AESTHETIC 

& CORRECTIVE GLOBAL BUSINESS UNITS 

06 

15

FOCUSED 

Achieving true potential 

Building a stronger position in the 

Aesthetic & Corrective and Selfmedication 

markets, while sustaining 

the high growth level in the core 

Prescription business are key. A new 

organization leveraging company 

resources and skills has therefore 

been set up. 

Answering dermatological 

needs throughout the world 

Galderma has experienced remarkable 

growth in recent years. In a short 

time span, the company has changed 

from an essentially dermatological 

prescription-based business into 

a worldwide leader with three global 

businesses in more than 70 countries: 

Prescription, Self-medication and 

Aesthetic & Corrective. 

Taken together, these businesses offer 

the most comprehensive range of skin 

health solutions available to patients 

and consumers worldwide. While activities 

share the same values, they 

function in different ways. Models 

and access to markets vary; customers 

may be patients, consumers, healthcare 

professionals, or all three; distribution 

channels and prescribers change depending 

on the country, and product 

launches and life cycle management 

differ. They all nevertheless have a 

common goal: to answer dermatological 

needs with the same level of engagement 

and innovation, of service 

and product quality. 

Reaching that goal requires specialized 

skills and a strong vision of the future 

of dermatology. Today, Galderma's 

commitment is to move from being 

a market leader to becoming a global 

company that shapes the dermatology 

market. Anticipating needs, reducing 

time to market and partnering closely 

with healthcare professionals and listening 

to patients and consumers are 

the vital steps to fulfilling this vision. 

Moving from a market leader 

to becoming a global company that shapes 

the dermatology market. 

A three-fold strategy 

In June 2012, Galderma announced its 

decision to create three Global Business 

Units (GBU); one for each of its 

cornerstone activities. Working with all 

the teams at regional and country levels, 

this new organization will offer a stronger 

strategic focus, consolidate skills and 

resources, and boost innovation and 

execution capabilities across different 

geographic regions. It represents a new 

way to conduct business, to better serve 

customers and patients. 

The first mission of the three Global 

Business Units is to sharpen the strategy. 

Making sure that the right products 

in the right portfolios are available on 

time; ensuring that high-potential solutions 

are being developed; and organizing, 

prioritizing and developing product 

ranges. As a result, the company is 

focused, investing and working on key 

markets where growth potential can be 

maximized. 

On a global level, product launches 

will accelerate. A new treatment for rosacea 

is expected to be rolled out over 

the globe after grant of market authorizations. 

This international launch is 

prepared by the Prescription Global 

Business Unit in very close cooperation 

with local markets. 

Excellence 

in aesthetics 

Located in Uppsala, 

Sweden, Galderma’s 

Global Center of Excellence 

concentrates the 

discovery, development, 

manufacturing, medical 

and regulatory affairs as 

well as strategic brand and 

channel management of 

the Aesthetic & Corrective 

(A&C) Global Business Unit. 

The state of the art R&D 

team drives the innovation 

on hyaluronic acid-based 

gels and in particular uses 

the patented NASHA 

technology to develop 

stabilized, non-animal 

hyaluronic acid-based 

products and also 

anticipate for the products 

of the future. The annual 

production capacity of 

10 million units spans a 

comprehensive portfolio of 

medical solutions. This is in 

total more than 400 people 

committed to the A&C 

business operating for 

Galderma in Uppsala. 

4 ,230 

EMPLOYEES WORLDWIDE. 

MORE THAN 

300 PEOPLE JOINED 

GALDERMA IN 2012. 

3 

GLOBAL BUSINESS UNITS 

WERE CREATED IN 2012, ONE 

FOR EACH OF GALDERMA’S 

CORNERSTONE ACTIVITIES. 

+12.9% 

THE COMPANY’S OVERALL 

GROWTH RATE IN 

2012 VERSUS 2011 (BASED ON 

REPORTED FIGURES). 

1.59 

BILLION EUROS: 

GALDERMA’S 2012 SALES. 

6.9% 

GALDERMA’S SHARE 

OF THE GLOBAL 

DERMATOLOGY MARKET. 

Source: IMS data - D+J1A+J2A 

(dermatology only), MAT 

December 2012 – 39 countries 

16 

17

FOCUSED 

Coordination between all functions 

makes it possible to plan this important 

operation seamlessly. It also shows a new 

way of functioning within the company: 

faster execution, more efficiency and offering 

better visibility to all involved. 

Transversal expertise 

The new organization impacts operations 

at all levels. Delivering demanddriven 

dermatological medical solutions, 

the company is offering its three 

categories of products and services on 

all markets. At country level, affiliates are 

now dealing with three families of solutions, 


Aesthetic & Corrective. Each category 

remains unique and different, requiring 

a high level of specialized knowledge 

and dedicated resources. The pivotal 

role of the local teams is strengthened 

by the transversal expertise provided by 

the specialized Global Business Units, 

so that together they deliver the best 

solutions and services to healthcare 

professionals and patients. Expertise in 

the Aesthetic field, for example, does not 

rest in the simple sale of a product. It is 

more specifically about providing the 

proper service to a physician and ensuring 

the best patient experience. It might 

well involve helping a doctor develop 

his practice in a field with which he is 

not necessarily familiar. In this respect, 

providing physicians with services such 

as training sessions is essential. Similarly, 

the role of the Global Business Unit goes 

beyond developing and manufacturing 

new products. It also helps to earmark 

resources and build comprehensive programs 

to better deliver the Aesthetic & 

Corrective experience. 

Leveraging opportunities 

Another challenge of the new organization 

is leveraging existing opportunities 

throughout the company. Sharing 

services, production facilities and R&D 

across all three segments is essential. 

Integrating operations by monitoring 

results, providing guidelines and best 

practices is a common need. New synergies 

are identified between the different 

categories of products. Self-medication 

products, for instance, are derived from 

Prescription solutions or developed independently. 

Specific Self-medication 

marketing know-how and packaging 

are optimized for other categories of 

solutions, on consumer-driven markets 

where brand perception is crucial. 

Focusing on simplicity 

Galderma’s commitment is to develop 

business by keeping in touch and answering 

market needs. The human factor 

is ever present. The challenge of working 

across divisions and Global Business 

Units is first and foremost a question of 

helping people work together efficiently. 

For that reason, the company aims for 

simplicity. An entrepreneurial spirit is a 

precious asset for any fast-growing company, 

and Galderma strives to nurture 

that mindset. Its new organization aims 

at helping employees reach their goals 

and fulfill their ambitions. The foundation 

may be based on strategy, products 

and timely execution, but ultimately it is 

about sharing the same passion for and 

commitment to dermatology. 

The challenge of working 

across divisions and Global 

Business Units is first 

and foremost a question 

of helping people work 

together efficiently. 

Galderma UK: new models and partnerships 

Galderma’s broadening 

focus and three business 

models strategy have 

received strong feedback 

from affiliates and some 

markets have been 

prompt to implement 

these changes. The 

UK context has been 

particularly challenging 

as dermatology has been 

gradually pushed outside 

of the treatment scope 

of the National Health 

Service. As a result, fewer 

patients are referred to a 

dermatologist; GPs and 

nurses are encouraged to 

prescribe and treat. The 

government even created 

a Pharmacy “P” category, 

which allows the patient 

to obtain a prescription 

product from the 

pharmacist, bypassing a 

physician’s consultation 

fee. “Over the next five 

years, Self-medication 

products are expected 

to rival our Prescription 

business,” observes Larry 

Potgieter, General 

Manager Galderma UK 

& Ireland. “We plan 

to increase the Selfmedication 

team to 

support the doubling of 

this business every three 

years, and expand on 

our capabilities in the 

Aesthetic & Corrective 

business.” Developing 

promotion campaigns 

and building business 

partnerships are key for 

the Self-medication skin, 

hair and nail categories. 

In 2012, Galderma UK 

implemented a media 

campaign for Curanail, 

resulting in 26% sales 

growth year-on-year and 

consolidating its 

leadership position in a 

highly competitive space. 

Another development is 

Galderma UK’s strategic 

alliance with Boots, leader 

in UK pharmacy retail. The 

partnership is structured 

to include Prescription to 

OTC switches as well as 

developing a ‘Serious 

Skincare Section’ in their 

pharmacies. As a result, 

Galderma UK reported 

a strong year, with a sales 

record of over €62 million 

in addition to winning 

numerous awards. These 

achievements reflect the 

priority of moving even 

closer to consumers while 

ensuring sales force 

excellence. 

Monitoring patient safety 

Vigilance Department collects, monitors and 

assesses adverse events reported in relation 

with use of Galderma products. Galderma’s 

close relationship with prescribers 

and authorities is key in facilitating the 

reporting of reactions to products. Often, 

healthcare professionals will mention the 

problems they encountered to Galderma’s 

sales representatives, who forward the 

information to a local safety officer, a local 

function in charge of product safety. 

All reports are processed in the company’s 

global database and assessed in terms of 

seriousness, listedness and causality. In 

2012, the company put in place a new global 

pharmacovigilance system, accessible 

for the main affiliates. Acting proactively, 

the same system will ultimately be used 

for product vigilance in the Aesthetic & 

Corrective field as well, in order to handle 

all vigilance issues regardless of the type 

of medicinal products (ie. drugs, medical 

devices or cosmetic) or any combination 

of these. Galderma is also actively adapting 

its processes to meet the new European 

legislation, with a shared emphasis on 

quality and compliance. Patient safety 

is ever the priority. 

+15.9% 53% 

GROWTH IN THE 

SELF-MEDICATION 

SEGMENT IN 2012. 

4.73 

DAYS OF TRAINING 

BY EMPLOYEE IN 2012. 

OF WOMEN 

A BALANCED GENDER 

DISTRIBUTION. 

18 

19

FOCUSED 

Engaged employees, 

empowered teams 

Alain Kirsch, Vice-President Human 

Resources, tells us about the first 

global employee survey conducted 

at Galderma. 

Why carry out a global 

employee survey 

Alain Kirsch: In 2012, we felt the moment 

was right, given the recent change 

and growth we had experienced. 

It was the right time to take the pulse of 

our employees, to find out how they felt 

in the company and what areas we could 

improve. 

What did the survey show 

AK: A very large amount of data! There 

is plenty to learn in the comments our 

employees shared with us as part of the 

survey. Overall, the results show higher 

positive scores than our sector, the pharmaceutical 

industry sector, and reflect 

the high level of engagement. Galderma 

is seen as a good employer. 

What actions will ensue 

AK: We will continue sharing our vision, 

strategies and ambitions. A bigger 

investment in training will be made, 

particularly in locations where learning 

activities were lacking. Several initiatives 

at global and local level are planned to 

improve people’s opportunities for developing 

employee evolution. Regarding 

organization effectiveness, delegation 

and empowerment, changes have 

been made, improving governance and 

project management prioritization processes. 

In response to the survey, many 

other initiatives will be launched in 2013. 

SURVEY: A VERY HIGH 

PARTICIPATION 

The global employee 

survey was conducted 

over three weeks in June 

and July 2012, through 

an online questionnaire 

made available by Towers 

Watson, an HR consulting 

firm. Employee participation 

was very high: 92% filled 

in the form and one person 

in two volunteered 

additional comments, a 

remarkable qualitative 

contribution. The main 

finding of the survey is a 

very strong engagement of 

all employees, from senior 

managers to support staff. 

72.4% 

AVERAGE FAVORABLE 

SCORE ACROSS ALL 

CATEGORIES, RANGING 

BY ITEM FROM 60% TO 

90%, VERSUS 70% IN THE 

PHARMACEUTICAL NORM, 

(RANGING FROM 57% TO 87%). 

90% FAVORABLE 

FEEDBACK ON “GOALS AND 

OBJECTIVES”, THE HIGHEST 

SCORE OF THE SURVEY, 

AND EVEN HIGHER THAN 

THE HIGH PERFORMANCE 

COMPANIES. 

61% FAVORABLE 

FEEDBACK ON “TRAINING”, 

THE LOWEST SCORE OF 

THE SURVEY. 

Empowering teams for optimal performance 

How does Australia’s 

performance reflect 

the level of employee 

commitment 

Given the changes and 

extraordinary growth 

(+35.1%) we were 

experiencing as a business, 

2012 was a critical period 

for managing compliance, 

commitment and 

communication. 

Our team was dedicated to 

achieving objectives that 

were clearly communicated 

and agreed upon. 

What initiatives were 

taken to further engage 

employees 

Staff received strong 

encouragement to 

reach beyond targeted 

objectives and find 

creative solutions within a 

framework. Management 

techniques were reviewed 

and employees helped to 

develop their knowledge 

and skills. All managers 

answered a 360° survey 

to identify best practices 

and areas of potential 

improvement for reaching 

superior employee 

engagement. Employees, 

in turn, were encouraged 

to be accountable for their 

results and empowered 

to “do business with 

customers”. Delegation and 

decision-making processes 

were optimized. Formal 

reports and customer 

reviews enabled staff to 

monitor and track results. 

What about improving 

team empowerment 

Effective knowledge 

sharing stimulates true 

employee empowerment. 

We actively promoted 

transparency, ensuring 

that expected outcomes 

were communicated, 

information was consistent 

and campaigns aligned. 

Business updates circulated 

via email, newsletters 

and presentations at 

sales meetings and staff 

communication sessions. 

How did individual 

training contribute 

We encouraged individuals 

to be accountable for 

their own learning and 

development, and provided 

access to an online selfdevelopment 

assessment 

tool. Employees received 

reports and strategic 

pointers to work on 

improvement areas. As a 

result, Australian employees 

are empowered to drive 

their own development, 

steer themselves and own 

their tasks. 

“Effective knowledge sharing 

stimulates true employee 

empowerment.” 

LISA GEORGE, 

HR MANAGER GALDERMA AUSTRALIA 

ETHICALLY ENGAGED 

Values, ethics and compliance 

are part of Galderma’s culture. 

The values set the framework for 

daily operations and are viewed as 

assets for the organization. High performance 

and high integrity are objectives 

that, far from clashing, work 

very well together. At Galderma, 

training and open dialogue related to 

ethics, compliance and legal topics 

are constants. Quality Assurance and 

compliance teams work hard to understand 

the business and always 

keep the company’s strategies and 

objectives in mind. 

Throughout the world, government 

and public scrutiny of the pharmaceutical 

industry is growing, notably 

regarding interactions with healthcare 

professionals. Relations between 

Galderma and healthcare professionals 

are transparent and 

focused on medical and scientific 

exchanges on diseases and their 

treatments. 

More generally, Galderma strives to 

meet the high standards of ethical 

practices in all its operations. The 

company’s Code of Ethics is more a 

statement of values and conduct 

than a set of rules. It addresses principles 

on interactions with healthcare 

professionals but also focuses 

on the patient and more generally 

people, caring for individuals and 

their balance, diversity and responsibility. 

The company requires employees 

to always act according to 

the Company values and Code of 

Ethics, with a strong reminder that 

the well-being of patients comes first 

and foremost. At Galderma, ethical 

behavior has no finish lines, we always 

strive to be better. 

20 

21

INNOVATIVE 

NICOLE LAUDIGNON AND 

THIERRY BILBAULT TALK ABOUT 

WHAT GOES INTO CULTIVATING 

INNOVATION THROUGH TEAMWORK, 

FROM EARLY R&D TO FULL-SCALE 

MANUFACTURING. 

How do you work together 

Nicole Laudignon: The Full Development 

Department develops products from their inception to 

their submission to Regulatory Authorities. Work with 

Manufacturing & Technical Operations (M&TO) 

begins at the very early stages of development, optimizing 

the progress from drug discovery to product 

development and full scale commercialization. Production 

knowledge and experience has to be transferred 

to M&TO as seamlessly as possible. 

Thierry Bilbault: Because we engage with R&D teams 

at the early development stage of a new chemical entity, 

we know which projects move into the scope of the Full 

Development team and when. Main deliverables and 

their timelines are determined together and monthly 

follow-up meetings on specific projects are held. 

How do you deliver an innovative medical solution 

NL: Our job is to design and develop innovative formulations, 

not only for new chemical entities but also 

throughout our products' life cycle management. 

TB: Beyond launching a product for the first time, innovation 

is how fast it can be rolled out to the rest of 

the world. Managing product life cycle is innovative: 

whether maintaining an existing solution on a market or 

finding new markets for it. Packaging must also be innovative, 

as we constantly strive to find the best way for 

patients to use a product with new features and benefits. 

...to delivering 

innovative 

medical 

solutions... 

NICOLE LAUDIGNON 

DIRECTOR OF FULL DEVELOPMENT 

(R&D) 

Tell us about a successful innovation… 

NL: Pliaglis Cream is a topical local anesthetic. It is applied 

as a cream and then dries to form a flexible membrane 

that can be peeled from the skin. The formulation 

of the product, composed of the two molecules, lidocaine 

and tetracaine, has been challenging: the “mixture” 

forms a homogeneous oil but needs to be integrated in a 

high water content to hydrate the skin. A solution for an 

optimized formulation was created by our development 

teams and successfully transferred to M&TO. 

TB: Working in tandem with the Full development 

team, in 2012 we launched, within 12 months after 

its transfer from Full Development to Manufacturing, 

Cetaphil Dermacontrol, a range of two cosmetic 

products designed for use in patients treated for acne 

including Cetaphil Dermacontrol Oil Control Foam 

Wash, a unique foaming formula packaged in an innovative 

packaging. Delivering a commercial product 

in fast track mode was a key deliverable and illustration 

of the speed-to-market process. 

THIERRY BILBAULT 

TECHNICAL DIRECTOR 

(M&TO) 

23

INNOVATIVE 

A unique capability 

in dermatological R & D 

Research & Development centers are 

spread across different continents to 

focus on local needs, discover new 

molecules and launch products able 

to help patients all through their lives. 

Innovation is built 

into Galderma’s DNA 

Today Galderma stands among the few 

companies capable of inventing, developing 

and bringing to market dermatological 

solutions that are truly innovative. 

The extent of its strong commitment to 

R&D and access to innovative technologies 

is reflected in an annual investment 

equivalent to 19% of the company’s 

sales. Beyond figures, creativity is also a 

mindset in all the company’s activities. 

The teams at Galderma’s major research 

facilities actively pursue creativity on a 

grand scale, through discovering and 

testing new molecules and compounds, 

adapting new packaging to new uses, 

and sourcing new functions and partnerships 

for existing products in cooperation 

with the world’s leading biotechnology 

companies and dermatological 

research units. 

Shaping the future 

At Galderma, innovation implies a global 

approach. It starts by observing and 

anticipating the global dermatological 

needs of patients, which are often very 

different in nature. 

Then, solutions are developed to answer 

these needs very specifically. Solutions 

are technology-based, in the broadest 

sense of the term, from molecules and 

new chemical entities (NCE) to various 

means of administration (oral, topical or 

injectable) and the regulatory status attributed 

to the solution, such as Prescription 

drugs, Self-medication products or 

Aesthetic & Corrective medical devices. 

Combining patient needs with innovation 

is what allows Galderma to contribute 

to shaping the future of dermatology. 

Galderma is the leader in filing patents 

within the field of dermatology. 

Patent champion 

If patent applications are an accurate 

measure of innovation, the results are 

consistent. For several years, Galderma 

has been the leader in filing patents 

within the field of dermatology, with 

over 50 applications registered each 

year. In all, the company has filed more 

than 6,500 patent applications and 

patents worldwide since its founding. 

Innovation patents cover new molecules, 

galenic formulas, dermatology 

indications, manufacturing processes, 

packaging and many other categories. 

Throughout the years, Galderma has 

continually supported core research 

activities. For Prescription drugs, these 

range from early discovery phases to 

regulatory submissions and span several 

main therapeutic areas like acne, 

rosacea, steroid-responsive dermatoses, 

pigmentary disorders and nonmelanoma 

skin cancer. At each stage 

and across every field, innovation is 

a constant, even for well-established 

products. For example, Epiduo, the 

most prescribed branded topical agent 

used in the acne therapeutic field in 

the world (1) , has just been approved for 

populations aged 9 to 11 in the United 

States: a powerful innovation, based 

on the evidence of an effective and 

A global R&D 

presence 

Galderma has research 

and development facilities 

in France, Sweden, the 

United States and Japan. 

The Sophia Antipolis site in 

France is the world’s largest 

R&D center specialized 

in dermatology and has 

a staff of about 500. The 

center hosts Galderma's 

in-house research, 

pre-clinical and core 

development activities. 

In Uppsala (Sweden), 

the Global Aesthetic 

Center of Excellence is 

dedicated to Aesthetic & 

Corrective treatments. Its 

80 researchers have built 

extensive expertise in the 

field of hyaluronic acid. 

The Princeton center 

(New Jersey, USA) is 

focused on clinical 

development projects, 

aiming at the registration 

of products in the US and 

Canada. Clinical studies 

also support regulatory 

submissions around 

the world. In Tokyo, the 

R&D team is dedicated 

to the development 

and registration of new 

products for Japan. 

Some of Galderma’s 

extensive clinical 

studies involve over 

1,000 patients in 30 to 60 

different locations. 

600 

MORE THAN 

600 EMPLOYEES IN THE 

SCIENTIFIC DIVISION. 

19% 

OF GALDERMA’S 

SALES ARE DEDICATED 

TO R&D AND ACCESS 

TO INNOVATIVE 

TECHNOLOGIES. 

57 

NEW PATENTS WERE 

REGISTERED IN 2012. 

6,500 

PATENT APPLICATIONS 

AND PATENTS HAVE BEEN 

FILED BY GALDERMA SINCE 

ITS CREATION. 

12 

NEW CHEMICAL ENTITIES 

ARE IN DEVELOPMENT AND 

7 PRODUCTS ARE CURRENTLY 

BEING TESTED IN PHASE II AND 

PHASE III CLINICAL STUDIES. 

24 

25

INNOVATIVE 

safety-driven solution. Major new 

Prescription products are slated for 

launch over the next three years. 

New areas of research 

Self-medication offers a world of possibilities 

for innovation. Research is required 

to switch a Prescription product 

into a Self-medicated solution and file a 

successful submission to regulatory authorities. 

Loceryl nail lacquer is a good 

example of a category switch, allowing 

patients to self-treat. In the short term, 

a number of new Self-medication formulations 

and brands are expected to 

address the needs of patients satisfactorily. 

Improving patient compliance also 

means developing innovative products 

that are easy to use. 

The Aesthetic & Corrective segment is 

also a core research area, with a dedicated 

Center of Excellence in Uppsala, 

Sweden, where research and development 

of hyaluronic acid gel-based treatments 

is carried out. A key area of development 

is how to optimize product use 

and achieve excellent results with two or 

three times less product injections, for 

instance. Another key focus is clinical 

research: consumers, physicians and authorities 

alike are expressing an ongoing 

need for evidence-based, safe products. 

Ongoing development 

R&D resourcing is constantly being 

driven forward. New people are regularly 

recruited to strengthen teams and 

expand expertise. Establishing new collaborations 

with the best partners possible, 

be they small biotechnology companies 

or large pharmaceutical groups, 

is also a key source of creativity. A partnership 

with a major biopharmaceutical 

leader, the innovation-driven AstraZeneca, 

is currently exploring compounds 

developed for other indications, which 

could prove very useful in dermatology. 

Licensing agreements with other industry 

partners also provide synergistic 

frameworks that give the company an 

innovative edge within strategic areas of 

research, such as rare skin diseases. 

In the critical field of skin cancer, where 

many medical needs are still left unanswered, 

Galderma further expanded its 

collaborations this year with two leading 

dermatologists and authorities on 

skin cancers, and their teams: Professor 

Martine Bagot, of the Saint-Louis 

Hospital in Paris, France, and Professor 

Madeleine Duvic, Deputy Chairman 

of the Department of Dermatology at 

The University of Texas, MD Anderson 

Cancer Center in Houston, Texas, USA. 

Major innovations in the pipeline 

Galderma’s large network of experts 

also contributes to research, notably 

through carrying out clinical studies. 

Some studies are very extensive, involving 

1,000 patients or more and 

span 30 to 60 different locations at a 

given time around the globe. Currently, 

twelve new chemical entities are 

in development and seven products 

are tested in Phase II and Phase III 

clinical studies. 

In terms of research volume, diversity 

and skills, Galderma is well-positioned 

to come up with great new solutions. 

It is even possible that the company is 

reaching a major turning point. Over 

the last decade, it has been highly successful 

in finding new molecules and its 

knowledge base has expanded considerably. 

A substantial number of major 

innovations are now in the pipeline. 

Over the next five years, the company’s 

portfolio of marketed products will 

be deeply renewed across categories. 

Finding innovative solutions for people 

around the world will continue to be 

the strongest contribution Galderma 

can make to the future of dermatology. 


all countries selected - Topical anti acne market - 

Nov.2012 MAT, retail Rx Market - at sales manufacturer 

local currency dollar value 

A partnership against antibiotic resistant impetigo 

Galderma has established 

a long-term Research 

and Development 

partnership with 

California-based biotech 

company NovaBay, 

to develop an effective 

treatment against 

impetigo and conduct its 

phase II clinical studies. 

Impetigo is a highly 

infectious bacterial 

skin disease that affects 

mostly children which, 

when left untreated, 

can lead to complications 

such as pneumonia 

or arthritis. Antibiotic 

treatments for the 

disease are increasingly 

obsolete, as the 

bacteria responsible for 

impetigo's transmission, 

Staphylococcus aureus 

and Streptococcus 

pyogenes, develop 

resistance to the agents 

used to overcome them. 

The non antibiotic, antiinfective, 

proprietary 

NVC-422 topical 

formulation (also known 

as Aganocide treatment), 

developed by the 

Galderma and NovaBay 

partnership, could replace 

traditional antibiotics 

in the treatment of 

impetigo. The topical 

NVC-422 preclinical and 

clinical safety has been 

established by Galderma, 

with the successful 

completion of studies 

involving more than 

300 healthy volunteers 

at 24 clinical sites in 

four countries, as well 

as the feasibility of 

manufacturing scale-up 

and long-term shelf life. 

In early 2013, the 

expansion of the phase IIb 

clinical trial for NVC-422 

will take place in South 

Africa. The incidence 

of the disease is known 

to be particularly high 

in tropical countries, 

including sub-Saharan 

Africa. "The treatment of 

impetigo is a significant 

unmet need in South 

Africa, and the expansion 

of this international study 

into that market is an 

important step for our 

partner Galderma," said 

Dr. Ron Najafi, Chairman 

and Chief Executive 

Officer of NovaBay. 

25,000 

SQ.METER 

THE SOPHIA ANTIPOLIS 

R&D CENTER IS GALDERMA’S 

LARGEST FACILITY. 

1,700 

SCIENTIFIC 

PUBLICATIONS IN 2012. 

9-11 

EPIDUO HAS JUST BEEN APPROVED 

AS AN ADDITIONAL INDICATION 

FOR POPULATIONS AGED 9 TO 11 

IN THE UNITED STATES. 

11,000 

MORE THAN 11,000 MOLECULES 

TESTED BY END OF 2012. 

1,750 

PHARMACEUTICAL 

REGISTRATIONS 

IN ALL GALDERMA'S 

AREAS OF EXPERTISE 

26 

27

INNOVATIVE 

Reactive and quality-driven 

manufacturing 

Internalizing production 

is a top priority for 

Galderma’s Manufacturing 

and Technical Operations. 

Because they are market-driven 

and flexible, Galderma’s Manufacturing 

and Technical Operations 

(the M&TO Division) provide an 

uninterrupted supply of the highest 

quality of Prescription, Self-medication 

and Aesthetic & Corrective 

products to affiliates and distributors 

around a fast changing world. 

Internalizing production 

At Galderma, manufacturing relies on 

four principles: safety, quality, service 

and cost efficiency. It is reviewed on an 

ongoing basis to provide the best level 

of performance while keeping unit 

costs in check. Market developments 

are also tracked closely, and processes 

are reorganized and adapted wherever 

growth potential is found. 

In 2012, 75% of Galderma products 

were produced internally, compared to 

15% in 2000. When demand for new 

solutions reaches critical mass and 

forecasts point to sustainable demand, 

the M&TO Division evaluates 

the opportunity to internalize 

production, further improving 

product supply, quality, safety 

and reducing costs. This ongoing 

effort at Galderma should reach 

an in-house production target of 

80% by 2020; the current production 

exceeds 120 million units per year. 

Leveraging Galderma's 

know-how 

The production facility in Alby-sur- 

Chéran (France) was opened in 1994 

and expanded to include the Industrial 

Development team in 1998. This 

site counts 270 employees, produces 

more than 40 million units per year and 

serves over 70 countries. 

The Industrial Development department 

spearheads development of clinical 

batches for trial worldwide, hones 

manufacturing processes for new 

products, acquisitions and transfers. 

In short, it is in charge of leveraging 

Galderma’s technical know-how, leading 

to improved global production 

performance. 

The Uppsala (Sweden) production 

site, formerly Q-Med, is part of the 

Center of Excellence for Aesthetic 

& Corrective solutions. As such, it is 

fully dedicated to the manufacturing 

of products in the aesthetics category, 

notably hyaluronic acid-based injectables. 

Uppsala counts 175 employees, 

and has an annual capacity of 10 million 

units, a production rate that allows 

the company to meet growing demands 

in the Aesthetic & Corrective dermatology 

market. 

Serving regional demand 

Since the year 2000, the manufacturing 

site at Baie d’Urfé (Canada) produces 

Prescription products for the US market 

and Self-medication products for all 

markets, in both liquid and semi-liquid 

formulas. Annual production here is 

65 million units, with a headcount of 

270 employees. 

Life cycle management brings more to products 

Patient needs differ 

from one region or 

country to another. 

Galderma life cycle 

management addresses 

these specificities while 

helping to keep products 

on a certain market or 

find new markets for 

existing ones. A classic 

example is switching a 

Prescription product 

into a Self-medication 

solution. In China, for 

instance, Government 

policy and consumer 

habits favor over-thecounter 

medication, and 

the rollout of accessible, 

effective consumerdriven 

brands suits local 

market conditions. 

In certain markets, 

products can also be 

updated to bring new 

benefits to patients. 

Introducing a new pump 

application system, 

for example, has been 

shown to improve patient 

compliance. Once a 

patient need is identified, 

a comprehensive 

presentation of technical 

options makes it possible 

to evaluate and test 

concepts or prototypes 

with patients and 

customers. 

The company’s Industrial 

Development team and 

associated packaging 

development teams 

oversee the execution 

of packaging-based 

initiatives that make 

a real difference to 

consumers and patients. 

The first challenge is to 

collect input from all 

relevant stakeholders 

including markets, global 

marketing, Research & 

Development, industrial 

sites and functions, 

then identify innovative 

and global packaging 

solutions that will meet 

required criteria: 

patient acceptability, 

technical aspects, cost, 

speed to market, etc. 

In 2012, examples of new 

life cycle management 

product launches in 

2012 included the US 

launches of Epiduo pump 

(under development 

for global roll-out), 

Differin 0.3%, Metrogel 

pumps and Clobex Spray 

Improved Nozzle. 

75 % 

OF GALDERMA PRODUCTS 

ARE SOURCED INTERNALLY. 

152 

MILLION UNITS 

PRODUCED IN 2012. 

800 

EMPLOYEES IN THE MANUFACTURING 

& TECHNICAL OPERATIONS DIVISION. 

+40% 

PRODUCTION CAPACITY 

AFTER PLANT EXTENSIONS IN FRANCE 

AND CANADA IN 2011. 

28 

29

INNOVATIVE 

Since 2004, a production site in Hortolândia 

(Brazil) has served the Latin 

American market; it also manufactures 

some solutions for the global market 

(excluding the U.S.). The site, which 

has a staff of 50, has a production of 6 

million units in liquid and paste form 

per year. However, Hortolândia’s capacity 

is quickly expanding in order 

to better serve a fast-growing regional 

market and anticipate new needs. 

Shaping a new industrial 

landscape 

The Alby, Baie d’Urfé and Hortolândia 

sites are ISO 14001 (environment) 

and OHSAS 18001 (safety) certified. 

All sites are regularly audited by health 

authorities such as the FDA (United 

States), ANVISA (Brazil), ANSM 

(France) or the KFDA (South Korea). 

The acquisition of Spirig, announced 

at the end of 2012, offers Galderma 

an opportunity to shape a new industrial 

landscape and forge a new path 

to the manufacturing of solids, one of 

the Swiss company’s areas of expertise. 

Spirig’s Egerkingen headquarters will 

become a Center of Excellence with a 

strong manufacturing arm. 

Galderma’s remaining production is 

outsourced to some 40 subcontractors, 

which comply with same set of specifications 

and requirements exercised 

by the company in its own plants. Each 

supplier is fully committed to applying 

the Galderma Code of Ethics, as part 

of the company’s general purchasing 

terms. A dedicated team of the M&TO 

Division works closely with subcontractors, 

who are audited according to the 

same key performance indicators observed 

in Galderma’s units. Nevertheless, 

internalizing production remains a 

top priority. The high standards of quality 

and productivity within the company 

make it possible to leverage 20% of 

costs when a product is manufactured 

in-house. 

Manufacturing at Galderma is in a 

constant state of flux: thanks to new or 

increased capacity, geographical expansion 

and market opportunities, production 

organization is striving for a leaner, 

more reactive and flexible outfit. 

Optimized supply chain 

“Flexibility” is the key 

word for Galderma’s 

future supply chain across 

the organization. One 

of the company’s main 

challenges for the future is 

serving consumer-driven 

market needs, as in the 

case of Self-medication 

solutions. This fast 

moving market is less 

predictable and more 

volatile than traditional 

product categories such 

as Prescription. To act 

quickly and efficiently 

on these segments, the 

company must involve 

all its main functions in 

product launches and 

structure a responsive 

supply chain. Specifically, 

the new organization will 

improve time to market 

for all products. A lean 

and transversal process 

is now in motion, based 

on a three-year roadmap 

and key performance 

indicators, involving both 

global business units and 

teams at market level. 

A pillar of future logistics 

is a new regional 

organization. Regional 

Sales and Operational 

Planning, for instance, 

will improve industrial 

resource management 

and support better 

sales forecast. Planning 

functions are combined, 

with a regional supply 

chain management for 

enhanced efficiency. The 

benefits expected from 

this new organization 

are decreasing air freight 

and reducing product 

obsolescence, inventory 

and subcontracting. 

An improved businessdriven 

process will bring 

significant savings to the 

company while serving 

market needs more 

efficiently. 

A 10-YEAR 

INDUSTRIAL PLAN 

DRIVEN 

BY GROWTH 

Over the next ten years, the 

company will focus on growth 

markets and increase its manufacturing 

capacity according to market 

potential. Bringing production 

closer to the demand is a logical 

move. Being able to manufacture 

in a more reactive and flexible 

way will meet market needs better. 

This priority is backed by a new 

transversal approach to manufacturing, 

in which dedicated teams 

track markets and strive to fully 

understand needs. This knowledge 

is then translated into a proactive 

production strategy. Since it was 

first implemented in North America, 

the growth-driven production 

principle has rolled out to Brazil, 

where Galderma’s Hortôlandia 

plant will expand to better serve 

this high-growth market and other 

Latin American countries. China, 

India and South East Asia are also 

priorities. 

4 

The 

MANUFACTURING SITES: 

FRANCE (ALBY-SUR-CHÉRAN) 

SWEDEN (UPPSALA), CANADA 

(BAIE D’URFÉ), AND BRAZIL 

(HORTOLÂNDIA). 

announcement 

of Spirig acquisition 

will bring additional 

manufacturing and 

R&D capabilities in 

Egerkingen. 

40 

SUBCONTRACTORS, COMPLYING WITH SAME SET 

OF SPECIFICATIONS AND REQUIREMENTS EXERCISED 

BY THE COMPANY IN ITS OWN PLANTS. 

At Galderma, manufacturing 

relies on four principles: 

safety, quality, service and 

cost efficiency. 

30 

31

WENDY ADAMS AND MARC 

WANNHOFF TALK ABOUT HOW 

GALDERMA GROWS AND 

EVOLVES THROUGH A CLOSE 

RELATIONSHIP WITH PATIENTS. 

helps address cost containment. Also, the Aesthetics 

& Corrective category is growing as the population 

lives longer. 

Mark Wannhoff: In Germany also, the interest in 

aesthetic solutions is growing. As the population ages, 

people want to look as good as they feel inside. 

SPECIALISTS 

...to meeting the 

dermatological 

needs of people 

throughout 

their lifetime... 

WENDY ADAMS 

GENERAL MANAGER 

GALDERMA CANADA 

What new needs are patients expressing today 

Wendy Adams: In Canada, ethnic diversity is prevalent 

and changing quickly. Patients want products 

that care for their specific needs and easier access to 

dermatologists. Fewer new medications are getting reimbursed, 

so increasing the Self-medication portfolio 

How are you responding to those needs 

MW: We don’t only offer selective treatments in dermatology; 

we provide a full approach. In Germany, almost 

100 sales reps have daily contact with customers, 

nearly 1,000 exchanges per day. That’s the basis for everything, 

and it cascades within our organization. We 

demonstrate our commitment to dermatology through 

funding various awards for scientific research in dermatology, 

for example, and market activities such as 

in-pharmacy patient information days and awareness 

campaigns, like the ‘Skin Health Days’ events held 

about 15 times per year. 

WA: We’ve been fortunate in putting products on the 

market for Prescription and Self-medication and we’re 

considering Pliaglis within our Aesthetic & Corrective 

business. We’re simplifying our solutions, which also 

helps with compliance. Patient education is a focus: we 

reach out to teens in their lingo and our Cetaphil club 

has over 30,000 online members. 

What future developments are you excited 

about now 

WA: We’ve begun installing computer terminals in dermatology 

and family physicians’ clinics to help educate 

patients. Dermatology is so visual: Galderma is leading 

the way with this initiative. 

MW: Interaction is key: getting feedback from patients 

about what they need and what has helped them deal 

with their issues in daily life is deeply gratifying. 

MARK WANNHOFF 

GENERAL MANAGER 

GALDERMA GERMANY 

33

SPECIALISTS 

A new dermatology landscape 

The field of dermatology is changing 

fast: the emergence of new markets, 

the maturing of established ones 

and the importance of the digital 

age demand targeted, customtailored 

and evidence-based solutions 

for patients, healthcare 

professionals and authorities alike. 

A tectonic shift is underway in the dermatology 

landscape. New populations 

of consumers are growing exponentially. 

People in traditional markets are 

changing how and where they consume; 

response to health reforms and a 

desire to age gracefully are also at play. 

Consequently dermatology is receiving 

a lot of attention and Galderma is 

spearheading the change. Its roll-out of 

innovative medical solutions in the Prescription, 

Self-medication or Aesthetic 

& Corrective segments has significantly 

increased, serving patients all around 

the world. For example, the creation of 

a Global Aesthetic Center of Excellence, 

in Uppsala (Sweden), underscores the 

company’s holistic commitment to better 

serving an expanding market. 

As new needs appear, Galderma is working 

closely with healthcare professionals, 

focusing on services, solutions and better 

serving patients. Building new product 

segments, focusing on demands, investment 

and reactivity, Galderma is organized 

to deliver a synergistic portfolio 

across its three businesses. By adapting 

offers to customers and practitioners 

within various markets, by remaining 

close to patient feelings and aspirations, 

the company has improved the dermatological 

experience for all. 

Responding to new market needs 

The population explosion in emerging 

countries has opened an important 

new area for dermatology: by 2030, 

80% of the global middle class will live 

there. The rise of younger, Internet 

Galderma is adapting its offers to customers 

and practitioners within various markets. 

and media-savvy consumers in places 

such as Asia, Eastern Europe, India and 

Brazil shows the importance in getting 

the right product to the right consumer, 

swiftly. Building trust is key. Thanks 

to demographics’, growing spending 

power and increasingly well-informed 

interest in proper skincare, Galderma 

has responded to strong needs across its 

three businesses within new markets. 

In the Prescription business, for example, 

treatments for acne and rosacea 

serve significant demand across regions, 

with Epiduo as a leading drug bringing 

efficacy and safety in the treatment of 

mild, moderate and severe acne. Recent 

launches such as Oracea, or the increasing 

interest in Rozex, even strengthen the 

comprehensive drug portfolio. In 2014, 

Galderma will reinforce this momentum 

with the roll-out of a new treatment of 

erythema associated with rosacea. 

Promoting synergies 

between markets 

While facilitating global roll-outs, the 

company is also capitalizing on lessons 

learned in new markets, leveraging 

them to better serve previously established 

ones. The strong support of 

specific innovative initiatives facilitates 

synergies among disparate markets, 

Cetaphil: an 

expanding asset 

Cetaphil products have 

offered patients effective 

and adapted cleansing and 

moisturizing skincare 

solutions for over sixty 

years. The range has 

evolved over the years to 

address more specific 

needs and today includes 

16 products. The Disease- 

Specific Product (DSP) 

range has been developed 

to meet the requirements 

of physicians for a specially 

adapted therapeutic 

skincare range, such as 

Cetaphil Restoraderm for 

people suffering from 

atopic dermatitis, the 

number 1 skin condition 

encountered by 

dermatologists. The recent 

launch of Cetaphil 

Dermacontrol provides a 

therapeutic skincare range 

for patients treated for 

acne, in particular, a face 

wash and facial moisturizer 

SPF 30 which make the 

daily treatment regime 

easier to follow. The DSP 

portfolio registers the 

highest sales growth of 

the brand: +37% in 2012. 

95% 

OF 1.4 BILLION NEW INHABITANTS 

IN THE WORLD OVER THE NEXT 

TWENTY YEARS ARE EXPECTED 

TO BE BORN IN ASIA AND AFRICA. (1) 

1 

BILLION PEOPLE 

IN 2030 WILL BE AGED 

OVER 65 YEARS BY 2030, 

VERSUS 8% TODAY (1) . 

(1) Source: U.N. Population 

Prospects, The 2010 Revision. 

+5.8% 

THE PROJECTED ANNUAL INCREASE OF GLOBAL 

HEALTH SPENDING UP TO 2020, OUTSTRIPPING 

PROJECTED GLOBAL ECONOMIC GROWTH. 

Source: Bain (2011), The Great Eight – Trillion Dollar 

Growth Trends to 2020. 

3.2 

BILLION PEOPLE WILL BELONG 

TO THE GLOBAL MIDDLE CLASS BY 2020, 

VERSUS 1.8 BILLION IN 2010. 

Source: OEDC Development Centre, The 

Emerging Middle Class. 

34 

35

SPECIALISTS 

with products from all portfolios earmarked 

to receive extra resources and 

focus. One of these products was the highpotential 

Restylane Skinboosters treatment. 

Two countries in different stages 

of development were chosen to source 

best practices: Mexico, a high potential 

market, and Sweden, with a solid customer 

base. After launching a campaign 

combining outdoor, print, digital and PR 

communications with an in-clinic campaign, 

Restylane Skinboosters established 

itself as the major aesthetic treatment in 

each market. 

Camp Wonder: a special 

summer for children with 

skin diseases 

Promoting international exchanges 

Today, healthcare reform dominates headlines 

in mature markets. Governments in 

Europe and around the world continue to 

cut costs by de-reimbursing certain categories 

of prescription treatments. Products 

become generic or over-the-counter 

and patients and consumers are increasingly 

forced to pay out of their pocket. 

A new market for reliable and value priced 

self-medicated dermatological solutions is 

emerging, in which Galderma is bringing 

innovative and high-quality offers. 

The ageing of the European population 

has created new needs. People remain active 

both inside and outside of the professional 

arena. Consumers want to look as 

good as they feel and an increasing number 

of quality injectors and techniques 

drive strong growth in the Aesthetic & 

Corrective category. Patient demand for 

more strictly regulated product approval 

and marketing of facial fillers favor evidence-based 

companies, such as Galderma. 

Building strong partnerships with authorities 

to ensure appropriate consumer 

safety is a necessity. 

To this end, Galderma is reinforcing its 

engagement in clinical studies worldwide, 

forging partnerships with academic institutions 

and organizations, supporting 

Young patients with chronic and lifethreatening 

skin diseases as well as their 

families are subjected to an unusual set of 

constraints. In the U.S., Galderma partners 

through the brand Cetaphil with the nonprofit 

Children Skin’s Disease Foundation, 

the founder of Camp Wonder. Camp 

Wonder is a free of charge summer camp 

in California, where 100 children aged 

7 to 16 can get a week away from stares and 

bullies and instead experience the childhood 

joys of summer camp. Acceptance and 

empowerment are the foundation of Camp 

Wonder’s philosophy. Counselors are 

often former campers, facilities are fully 

educational programs like Euroderm 

Excellence (see page 43). Promoting better 

knowledge of dermatology, diseases 

and treatments, the company has devoted 

considerable energy and investment 

to supporting global and local congresses 

in the field. It vows to promote exchange 

and attain a deeper understanding of what 

physicians and patients are looking for 

now and in the future. 

Connecting with people 

Today, Galderma is an industry leader 

in anticipating patient needs, researching 

and developing new ideas. Experience 

demonstrates that, no matter what 

the medical field or platform may be, 

investing time in cultivating relationships 

and exchanging information will always 

be an organization’s greatest strength. 

In times of change, the best way to prepare 

for the future is to connect with 

people. All of them. 

handicapped accessible and activities are 

tailored for every camper’s needs. A large 

on-site medical staff of volunteer physicians, 

nurses, medical students and other 

healthcare professionals offer children a safe 

and happy experience. As a proud supporter 

of Camp Wonder, Galderma provides a 

generous grant and employee volunteers 

during the camp and throughout the year. 

Learn more on: http://www.csdf.org 

Lena’s aesthetic treatment 

“I decided to have some 

aesthetic treatment when 

I discovered that the older 

I got, the more I was 

fighting a losing battle 

against gravity. Everything 

started going downwards! 

It is a fact of life, but 

nonetheless a sad one. 

So when I realized you can 

do something about it 

without a major procedure, 

I set up a time for a 

consultation with a clinic. 

I wanted to do something 

about my tired-looking 

eyes. Also, the wrinkles 

around my mouth made 

me look annoyed and 

irritated, which is really 

something I am not! I was 

surprised at how little time 

it took to do the treatment, 

I had thought it would be 

much more complicated, 

but it only took half an hour 

and wasn't dramatic at all. 

I got a small bruise from the 

injection, but could easily 

cover it with a concealer 

and no-one could see 

anything the day after. 

While I was at the clinic, 

I learned about the 

skinboosters and 

became curious about 

them, because my 

skin was a bit dry. 

I booked a series of 

treatments, as you have 

to repeat them for 

maximum effect. 

I am amazed when I look 

at the results today. 

“It has really been a lift for me 

mentally as well. I think the 

connection between looking good 

and feeling good is really strong.” 

LENA AUGUSTSSON , 

STOCKHOLM, SWEDEN 

I feel a lot fresher now, 

I think the treatments have 

made me look at least 

6–7 years younger. 

It has really been a lift 

for me mentally as well 

because I think that 

the connection between 

looking good and feeling 

good is really strong. 

The funny thing is that 

although a lot of people 

have told me I look much 

more alert now, no one has 

suspected anything or 

asked if I have had a 

procedure done. Which 

is quite amazing, because 

I can easily tell the 

difference from looking 

at photos of myself before 

and after the treatment.” 

IMPROVING MEDICATION 

AGAINST ROSACEA 

Leader on the rosacea market, 

Galderma is about to bring to 

market a new solution for redness, 

subject to approval by 

health authorities. Rosacea is a 

common, chronic inflammatory skin 

disease. Fair-skinned individuals and 

women tend to be more prone to the 

disease. Both genetic and environmental 

factors may be involved in 

the pathogenesis, but research has 

yet to reveal its exact causes. Sufferers' 

most frequent complaint is about 

intense redness of the facial skin, often 

accompanied by flushing, visible 

blood vessels and pimples. Rosacea 

can cause emotional distress including 

embarrassment, anxiety and low 

self-esteem. This is a major reason 

why the proper treatment of rosacea 

through the improvement of the 

physical signs and symptoms of the 

disease can contribute to patients’ 

psychosocial well-being. While there 

is still no cure for rosacea, Galderma 

has long been the leader in providing 

sufferers with effective and safe treatments 

like Rozex/Metro and Oracea. 

On condition of its approval by 

health authorities, Galderma should 

offer a new innovative treatment for 

the erythema of rosacea. In clinical 

studies, once daily application of the 

gel was well-tolerated, offering fast 

and durable relief from redness. It 

would be the first approved medication 

specifically developed to directly 

target the erythema of rosacea. As 

part of Galderma’s holistic approach 

to providing innovative dermatological 

solutions, besides prescription 

drugs, patients need to be counseled 

about potential trigger factors for rosacea 

and on the use of gentle, nonirritating 

skin care products. 

36 

37

SPECIALISTS 

Galderma’s key 

therapeutic areas 

ACNE 

ROSACEA 

PIGMENTARY 

DISORDERS 

ONYCHO- 

MYCOSIS 

PSORIASIS 

SKIN 

SENESCENCE 

SKIN CANCER 

RARE SKIN 

DISEASES 

Acne is a chronic 

inflammatory skin disease of 

the pilosebaceous gland, linked 

to changes in hormone levels, 

the condition can last several 

years. Acne occurs when the 

follicular canals of the gland 

become blocked with excess 

sebum (a fatty secretion) 

and dead cells and presents 

as inflamed pustules and 

painful red pimples, most 

commonly on the face, but 

also on the back and chest. 

Rosacea is a chronic 

inflammatory skin condition 

characterized by facial redness, 

which is by firstly intermittent 

but then becomes permanent. 

The disorder, which affects the 

T-zone (nose, cheeks, forehead 

and chin), can produce other 

symptoms such as broken 

blood vessels and, occasionally, 

papules and pustules which can 

look like acne. Rosacea mostly 

affects people between the 

ages of 30 and 60 and tends 

to occur more frequently 

among fair-skinned individuals 

with light-colored eyes. 

Two to five percent of North 

Europeans and Americans 

suffer from this disorder. 

Pigmentary disorders are 

characterized by an increase 

or decrease in skin pigment. 

Melasma (commonly 

known as the pregnancy 

mask) is the most frequent 

disorder, affecting 50 to 70% 

of pregnant women. This 

hyperpigmentation disorder 

can occur following exposure 

to the sun or hormonal changes. 

Vitiligo is a pigmentary 

disorder that affects 0.5 to 2% 

of the global population. It is 

characterized by white patches 

on the skin, usually on the face, 

hands, feet and frictional areas. 

Onychomycosis (or nail 

mycosis) is an increasingly 

common disorder, affecting 

around 10% of the world 

population. One in two people 

over the age of 70 suffers 

from it. Onychomycosis is 

caused by a microscopic fungus 

and tends to be more common 

in the toe nails. It is a highly 

contagious disorder that can 

destroy the nail if not treated. 

Psoriasis is a chronic, 

inflammatory skin disorder 

characterized by red, scaly 

and sometimes itchy patches. 

It affects around 2 to 3 % of 

the world population. 

It is a lifelong condition with 

relapses and remissions that 

are both emotionally and 

physically stressful. Psoriasis 

often develops on the scalp 

and nails, and can involve 

swelling and pain in the joints 

(psoriatic arthritis). There is 

currently no cure, but existing 

treatments help sufferers 

manage their symptoms. 

Skin aging is caused by the 

passage of time, but also by 

exposure to the sun and UV 

rays (photoaging). Its effects 

can be treated with drugs and 

medical procedures such as 

injections or laser therapies. 

Actinic keratoses are 

precancerous lesions frequently 

found in fair-skinned patients, 

especially with chronic sun 

exposure. The lesions appear 

as rough, scaly patches on 

sun-exposed areas of the body. 

If left untreated, they can 

develop into a fast-evolving 

form of skin cancer called 

squamous cell carcinoma. 

Basal cell carcinoma is the most 

common skin cancer among 

fair-skinned people. It affects 

mainly sun-exposed areas of the 

skin. It is not life-threatening, 

but the carcinomas enlarge, 

become locally invasive and 

can ulcerate. Melanoma is a skin 

cancer developing from cells 

producing melanin in the skin, 

known as melanocytes. 

It is the most life-threatening 

skin cancer, and often 

presents as an asymmetric 

pigmented lesion with irregular 

borders. Any change in its 

color, size or shape requires 

immediate consultation with 

a dermatologist. 

Galderma is currently exploring 

the treatment of few rare skin 

diseases. Congenital ichthyosis 

often occurs in a severe form 

in the first years of life. Later on 

it causes thick, dry, white scales 

to appear on the skin which can 

be debilitating in their more 

severe forms. Palmoplantar 

keratodermas are characterized 

by an abnormal thickening of 

the skin on the palms and soles. 

Cutaneous T-cell lymphomas 

result from uncontrolled 

proliferation of T lymphocytes. 

Clinically, it is evidenced by 

red scaly patches which are 

sometimes pruritic and can 

evolve into cutaneous, lymph 

nodes or visceral tumors. Gorlin 

syndrome is an inherited disease 

mainly affecting the skin and 

causing basal cell carcinomas 

to appear early in life. 

38 

39

PARTNERS 

PARTNERING WITH HEALTHCARE 

PROFESSIONALS TO DELIVER VALUE 

IS A PRIORITY FOR BENOIT CHARDON 

AND BRIAN JOHNSON. 

How do you best serve healthcare professionals 

in your markets 

Benoit Chardon: The Aesthetic & Corrective business 

is driven by physicians. Beyond supplying innovative, 

high-quality and safe products, we help them 

build their practices. Our Alliance Service Program 

includes advanced medical education, patient management, 

business consulting, merchandising and soon an 

e-learning platform. 

Brian Johnson: We meet practitioners every day and 

understand their medical and business needs. Explaining 

how new treatments serve their practice helps 

them. Patients’ needs change and clarify: it is easier 

to exchange with physicians when we have the right 

solution for them. We also support continuous medical 

education programs for dermatologists. 

Adherence and Performance) program for Epiduo 

helps teenagers and young adults follow their treatment 

and interact with the brand. We participate in 

disease awareness programs like “Face-to-face” for 

rosacea, and support events like those organized by the 

National Psoriasis Foundation. 

BC: In South Korea and China, we launched a successful 

Restylane celebrity campaign on TV, building 

market and brand equity. In EMEA & Latin America, a 

disruptive “before & after” campaign in waiting rooms 

associated for the first time premium quality photos 

with real-life people testimonials. Direct to consumer 

communication is considered by healthcare professionals 

as one of the best business drivers. 

BRIAN JOHNSON 


PRESCRIPTION MARKETING 

GALDERMA USA 

What has changed in your service 

to healthcare providers 

BC: With new research on consumer behavior towards 

aesthetic procedures, physicians understand better 

their new role in serving consumers. They realize that 

“patients” are expecting a premium service rather than 

a treatment for illness. 

BJ: We help practitioners provide value in new situations, 

by providing the widest range of innovative 

products and services. For example, Tri-Luma, the 

only FDA-approved treatment for melasma, can now 

be either dispensed by the physician in his office or 

prescribed to the patient. 

...while serving 

healthcare 

professionals... 

How do you talk directly to patients 

BJ: We help patients understand their disease and 

improve their experience. The TAP (Treatment, 

BENOÎT CHARDON 

HEAD OF FACIAL AESTHETICS 

41

PARTNERS 

A professional commitment 

With the Internet and new forms of 

media, the dependence of patients 

on a healthcare professional’s advice 

has changed. Like elsewhere, 

proactive self-education and 

shared responsibility are strong 

trends in dermatology. 

Partnering with professionals 

Galderma shares with healthcare professionals 

the mission of finding the 

right solutions for the changing needs 

of patients. A key part of that goal is 

developing partnerships with these 

professionals, to help them understand 

and better explain treatment benefits to 

patients who are more aware of their 

condition than before. Dermatologists 

are the most highly qualified medical 

professionals to deal with skin conditions, 

but there are many other healthcare 

providers who help patients find 

the right treatments for their needs. 

Among them, general practitioners, 

pediatricians, plastic surgeons, oncologists 

and gynecologists are increasingly 

treating skin conditions. Nurses are in 

constant contact with patients. Pharmacists 

play a key role in ensuring that 

the right products and solutions reach 

the patient, particularly in the case of 

Self-medication. 

Galderma engages with all of these 

professionals in a transparent and 

open way. Clinical studies provide 

a very practical point of contact 

with healthcare professionals. They 

offer physicians a firsthand view 

on Galderma treatments and their 

effectiveness. The company’s diligence 

on pharmacovigilance is another 

valuable contact point. 

Helping future practitioners 

Programs sponsored by the company 

are essential to the relationship with 

professionals. With the guidance 

of the Medical Affairs department, 

Helping healthcare professionals understand 

and better explain treatment benefits to patients. 

Galderma is supporting a number of 

initiatives to provide valuable services 

helping physicians in their daily 

practice of dermatology. Furthermore, 

the company is also committed to 

supporting a high level of education for 

dermatology residents. The residents’ 

program (see box on the right side), 

which the company supports through 

the European Dermatology Forum, is 

a seminar that puts future practitioners 

in touch with leading authorities in 

dermatology. Another initiative, which 

Galderma supports in the United States, 

helps student residents prepare for their 

final board examination in dermatology. 

Improving professional experience 

In the Aesthetic & Corrective field, 

training physicians in procedures is 

central and provides ample resources 

for better understanding of their 

needs. Some are medical, such as 

demonstrating how physicians should 

use new product injection techniques 

for better results and an enhanced 

patient experience. But change is 

also afoot in the way physicians run 

their aesthetic practice. These courses 

provided by Galderma, part of the 

Alliance Service Program, help 

professionals improve their practice 

management and patient service. 

A new generation 

of European 

Dermatologists 

The European Dermatology 

Forum (EDF) organizes 

Euroderm Excellence, an 

annual training program 

for European Residents in 

dermatology. Galderma is 

the exclusive sponsor of this 

program that provides 

strong academic value for 

students, bringing qualitative 

and practical knowledge 

to them. The course gathers 

the best dermatology 

residents from European 

countries. This 4-day 

training program in practical 

clinical dermatology deals 

with all aspects of research 

and practical skills. Since 

the beginning, over 1,400 

students and 100 of the most 

famous teachers have 

joined this international 

training course. It is a great 

opportunity for all 

participants to develop 

their professional network 

and further their skills and 

education. This event is 

shared across universities 

all over Europe, and the 10 th 

anniversary will be 

celebrated in 2013. 

45 % 

OF DERMATOLOGY DRUGS 

IN NORTH AMERICA ARE PRESCRIBED 

BY DERMATOLOGISTS, 33% 

BY GENERAL PRACTITIONERS 

AND 19% BY PEDIATRICIANS. 

Source: Wolters Kluwer. 

19% 

IN JAPAN, ACNE-RELATED 

PATIENT CONSULTATION RATES 

JUMPED FROM 14% TO 19%, 

FOLLOWING AN ACNE AWARENESS 

PROGRAM SPONSORED BY 

GALDERMA. 

30,000 

PEOPLE IN CANADA 

ARE MEMBERS OF THE 

CETAPHIL SKINCARE CLUB. 

The purpose of Galderma's 

Harmony Program is to teaching 

aesthetic physicians to achieve 

good, balanced results with 

2 to 3 injections, versus up to 10. 

1,000 

THE AVERAGE NUMBER OF 

DAILY CONTACTS BETWEEN 

HEALTHCARE PROFESSIONALS 

AND GALDERMA’S 

SALES FORCE IN GERMANY. 

42 

43

PARTNERS 

Likewise, Galderma’s Harmony program 

offers a complete holistic diagnostic 

approach so that physicians can 

listen to patients better and understand 

what they expect from an aesthetic 

consultation. 

Providing reliable 

information 

Communicating with patients is part 

of Galderma’s commitment. This includes 

educating them, helping them 

consult a doctor and understanding 

their disease and its treatment. With 

the Internet, patients are exposed to a 

huge amount of information, not all of 

it accurate or complete. The company 

works with medical institutions and patient 

advocacy groups all over the world 

to provide patients with the most appropriate 

and reliable information. 

Treatment compliance is a big issue. 

Reaching out online 

To encourage new means of exchange 

and interactions amongst dermatologists 

and healthcare professionals, Galderma 

supports online educational platforms and 

services. Among them, Dermquest.com 

is a website dedicated to practicing and 

future dermatologists. It features one of the 

Ensuring that the patient follows prescriptions 

precisely, in the right quantity 

and frequency, is essential. Often, 

the answer lies in product innovation. 

Offering Epiduo in a pump format has 

improved acne treatment compliance 

for teenagers. A mobile application allows 

Epiduo patients to track progress 

and share with their practitioners. The 

growing importance of Self-medication 

has prompted Galderma to step up its 

efforts in patient education. Initiatives 

such as online Cetaphil clubs have 

built large communities. Sometimes, 

people do not know that there is a 

medical solution for what ails them. 

In Germany, “Skin Health Days” are an 

important disease awareness campaign 

about rosacea, which informs those 

suffering from that condition on how 

it can be treated. Feedback has been 

overwhelming. 

largest image bank with more than 23,000 

photos available, expert opinions, case 

notes and resources relevant to the practice 

of dermatology. A panel of respected 

international dermatologists sits on the 

editorial board and helps continuously 

improving the platform in order to meet the 

needs of its members. Derm101.com offers 

access to the most current research about 

Building confidence 

Helping people acquire a better awareness 

of skin conditions and treatments 

contributes to building a virtual circle 

between patients and healthcare professionals. 

Ultimately, positive patient experiences 

delivered via the right solution 

prescribed or recommended by wellinformed 

healthcare professionals are 

what count most at Galderma. Good 

experiences and testimonials serve as 

reminders that people are at the heart 

of everything the company does. 

diagnosis and treatment of skin diseases, 

and the platform is also tailored to meet the 

specific needs of pediatricians and family 

physicians practicing dermatology. The 

new mobile applications in both English 

and Spanish make this platform even more 

accessible and helpful in the daily practice. 

More than 50,000 physicians in the world 

are already members. 

Caring for the Littlest Patients 

Dr. Manju Elizabeth George 

is pediatric dermatologist 

in Palm Beach Gardens, 

Florida. She is boardcertified 

in adult and 

pediatric dermatology. 

What new dermatological 

needs are you now seeing 

in your practice 

In my practice I am now 

encountering younger 

children (ages 8-10) and 

adolescents with acne. 

Also, there are many infants 

and children with atopic 

dermatitis (eczema), 

whose parents are highly 

knowledgeable: they 

prefer organic and natural 

products, they know 

about parabens and are 

environmentally aware. 

Is it difficult for patients 

to follow treatment 

protocol 

Yes, at times it can 

be difficult because 

medications and treatment 

protocol can be 

complicated. I often 

provide handouts and write 

out instructions clearly, 

numbered in order. 

Very often, I show parents 

how to apply a medication. 

I always ask them to call 

the office if they have 

any questions and 

tell them, "Things should 

be getting better, not 

worse so please call me.” 

How do you work 

to improve 

patient outcomes 

I often tell patients, 

"I can give you all the 

products you want but if 

you don't use them it 

doesn't matter". If patients 

like the product, they will 

use it. Patient satisfaction 

and tolerability are key. 

How do you work 

with Galderma 

I work with Galderma in 

developing acne education 

in the pediatric world, 

for providers who may be 

seeing acne first line 

in their office. I really enjoy 

talking to the community 

about something 

we can all prevent. 

What does interaction 

with Galderma bring you 

as a physician 

Galderma is providing me 

with all the resources I need 

as a practitioner: studies 

and handouts help me 

understand a particular 

product. I also learn from 

other pediatric 

dermatologists and 

pediatricians and this 

interaction really makes me 

a better physician. We all 

learn from each other. 

pediatricdermpb.com 

"I really enjoy talking to the 

community about something we 

can all prevent." 

DR. MANJU ELIZABETH GEORGE, 

PEDIATRIC DERMATOLOGIST 

CLOSE TO 

PHARMACISTS 

Galderma takes special pride 

in working closely with pharmacists. 

As one-stop providers 

for many solutions and products, 

pharmacies not only distribute Prescription 

products, naturally, but 

also the fast-growing category of 

Self-medication solutions, which 

pharmacists recommend to patients 

and consumers. In Brazil, for example, 

Galderma has developed a close 

partnership with pharmacies, offering 

a variety of services in about 

3,000 pharmacies. With over 425 

events in 2012, impacting almost 

7,500 pharmacists and their assistants 

in the different categories and 

brands of Galderma products, the 

company has shown its long-term 

commitment to this relationship. 

Special Cetaphil and Dermotivin 

corners were set up and pharmacists 

received training sessions for 

Loceryl. Many new or emerging 

markets, such as Brazil or China, 

rely increasingly on Self-medication 

brands; Galderma is helping pharmacists 

better serve their customers 

while delivering high-quality training 

and materials. 

44 

45

INTERNATIONAL 

TODD ZAVODNICK 

SENIOR REGIONAL 

DIRECTOR LATIN AMERICA 

THREE EXECUTIVES DISCUSS HOW 

GLOBAL STRATEGY WAS ALIGNED 

WITH LOCAL BUSINESS MODELS TO 

BOOST GROWTH IN 2012. 

How did you overcome market challenges 

Lee Heeson: In light of a challenging economy and loss 

of exclusivity, generating demand through our promoted 

brands across the 3 businesses was key. By focusing 

on cornerstone brands in Self-medication – Loceryl, 

Cetaphil and Benzac – and through talent acquisition 

and development, we successfully started the journey 

to create the dermatology category in pharmacies. The 

total value proposition of our world-class facial injectables 

portfolio, injector training and practice development 

support enabled us to drive market share gain in 

the A&C market. Finally, leadership development was 

a major focus with particular emphasis on strategic vision 

and agility. 

What is driving growth in your areas 

Todd Zavodnick: Latin America is a region where 

our main focus is to drive brand development and also 

shape and expand the overall market with initiatives 

across the three businesses. We expect strong double 

digit growth from all three business units within the 

current 10-year plan horizon. A key focus for us in Latin 

America is the expansion of the Aesthetic & Corrective 

marketplace, as today only 39% of physicians and 

surgeons are participating in non-invasive Aesthetic 

& Corrective procedures. We are executing numerous 

training initiatives to help grow the market in quantity, 

but at the same time ensuring they are quality injectors, 

achieving successful, repeatable outcomes over time. 

The commitment to our people and their development 

is of the utmost importance to achieve our objectives 

for today and tomorrow. 

What have been the strong points in your region 

Kamal Abbasi: Firstly the ‘can do’ attitude prevailing 

across the APAC region. The Asian economic boom and 

demographic shift, along with the increase of disposable 

income, and higher expectation on quality are benefiting 

our existing brands and is key for the future portfolio. 

It is expected that China will soon be the second 

biggest pharmaceutical market in the world. Restylane 

is successful and growing fast, with an Aesthetic & 

Corrective business in China showing strong potential. 

We also sold 5 million units of Cetaphil in China –the 

second highest performance in units after the U.S. 

Australia, our most successful affiliate to date, has 

become a benchmark for us in our 3 business strategy 

execution. In Korea, Cetaphil, recommended by 

dermatologists, took advantage of a business model 

including innovative online presence. 

...around 

the world. 

LEE HEESON 

SENIOR REGIONAL DIRECTOR 

EUROPE, MIDDLE-EAST, AFRICA 

KAMAL ABBASI 

SENIOR REGIONAL 

DIRECTOR ASIA-PACIFIC 

47

INTERNATIONAL 

Positioned 

for worldwide growth 

Following a year of growth in 2012, 

Galderma is preparing for another 

year of promising results driven 

by innovation. It is also a time of 

geographic expansion, with 

products available in more than 70 

countries and improved coverage 

in areas where the company was 

already present. 

A complete spectrum 

of solutions 

Galderma’s global strategy relies on the 

simple principle of bringing innovative 


Aesthetic & Corrective solutions to patients 

and customers in every market 

where there is a need. Galderma aims to 

strengthen its presence with patients 

and healthcare professionals by means 

of a vast portfolio of innovative medical 

solutions for everyone, at every age. 

This strategy then determines the company’s 

structure, notably as seen in the 

creation of new global business units. 

Strong brands are Galderma’s key asset. 

Four of them are ranked in the Top 20 

in the dermatology Prescription segment 

(1) . Epiduo is the most prescribed 

branded topical acne agent in the 

world (2) . Oracea, the first systemic treatment 

for rosacea, has met with huge 

success of sales in countries where it has 

been introduced. Loceryl, originally a 

Prescription brand, illustrates the potential 

of re-categorizing products as 

Self-medication: in Germany, sales of 

Loceryl have risen sharply since this 

treatment for fungal nail infections was 

made available over-the-counter in 

pharmacies. In the Aesthetic & Correctiveaera, 

Galderma can rely on a complete 

spectrum of solutions for medical 

practitioners, with its hyaluronic acidbased 

dermal fillers (Restylane and 

Emervel), a botulinum toxin type A 

(Azzalure), and complementary products 

such as Pliaglis and Metvix. 

Galderma is strongly focusing on new markets, 

particularly Asia and Latin America. 

Continued expansion 

In 2012, the Company recorded overall 

sales growth of 12.9% based on reported 

figures, with particularly good results 

in Germany, China and Australia. 

Mature markets generally consolidated 

their performance in 2012. In North 

America, the dermatology market 

transformed in 2012: reshaping of the 

competitive landscape, healthcare 

changes and generics exposure for 

branded drugs. In this challenging environment, 

Galderma continued its expansion 

during a year marked by five 

product launches and three registrations 

in both the United States and 

Canada, where Galderma is a leader in 

the Prescription market with strong 

growing brands. As recessionary 

Europe tightens its public medical coverage, 

Germany leveraged commercial 

efforts and advertising campaigns. 

Focusing on emerging markets 

There is a clear demarcation between 

mature countries and the bustling 

emergent markets, which are a strong 

focus for Galderma. Asia and Latin 

America are still in growth mode as 

markets take shape. Opportunities 

abound, both through the launch of 

products already available elsewhere 

China: 

a clear priority 

The company’s objectives in 

China are clear: to reinforce a 

leading Aesthetic & 

Corrective business while 

accelerating the Selfmedication 

and Prescription 

categories through 

developing local organizational 

and production 

capacities. A&C and Selfmedication 

are strong growth 

drivers. In A&C, Restylane has 

drawn more customers 

through increased brand 

equity and geographical 

coverage. Cetaphil continued 

to grow fast via increased 

distribution to drugstores 

and chain pharmacies. The 

Self-medication market holds 

great promise for switch 

products based on 

Prescription formulas, such 

as Loceryl Nail Lacquer. The 

Prescription portfolio is being 

actively developed and will 

add significant growth 

opportunities moving 

forward. In 2012, Galderma 

doubled its sales in this 

strategic market. 

No. 1 

US DERMATOLOGISTS RECOGNIZED 

GALDERMA AS NO. 1 DERMATOLOGICAL 

COMPANY FOR SEVEN CONSECUTIVE YEARS. 

Source: SDI Company Image Survey. 

Results in Dermatology, 2011. 

No. 2 

BRAZIL WAS GALDERMA’S 

SECOND LARGEST MARKET 

AFTER THE US IN 2012. 

Source: Company data, at the end 

of 2012, at comparable rates. 

8% 

THE COMPANY’S 

GLOBAL HEADCOUNT 

INCREASE IN 2012. 

58 

MILLION EUROS 2012 GALDERMA 

SALES IN GREATER CHINA (1) . 

17% 

GALDERMA GREW OVER 17% 

IN GERMANY DESPITE CHALLENGING 

MARKET CONDITIONS (1) . 

(1) Source: Company data, at the end 

of 2012, at comparable rates. 

48 

49

INTERNATIONAL 

and through investing in new regions, 

such as South East Asia. Among the leading 

market-building opportunities are 

Singapore, the Philippines and Indonesia, 

(one of the most highly populated 

countries in the world), followed by Malaysia 

and Thailand. 

Powerful opportunities 

In Asia, and perhaps around the world, 

China presents the highest potential for 

growth. With three-digit sales growth in 

2012, China is set to become the 

world’s second-biggest market for 

pharmaceuticals in the next five years. 

Galderma has been operating there for 

several years, and 2012 marked the beginning 

of its expansion in this area, 

with the inauguration of an affiliate, 

and sales doubled in 2012. Australia 

also performed very well, with a strategy 

based on the three businesses and 

Dysport, Cetaphil and Epiduo as key 

growth drivers. In Latin America, the 

rise of the middle class eager to spend 

on medical and consumer products to 

improve wellness has mirrored Galderma’s 

capacity for training physicians on 

treatment solutions. Both new markets 

and brands are expanding rapidly. Brazil 

represents the largest potential, reporting 

60% of the region’s total revenue 

and high opportunity across 

categories but many other markets, 

such as Mexico, are showing a strong 

increase in patient-driven needs. 

Responsible growth 

Because the company now serves nearly 

7% of the world’s dermatology market 

(1) and is investing in high potential 

markets, it is poised for further growth. 

The organic growth strategy is complemented 

by its external growth strategy. 

For example, in December, the brand 

announced the acquisition of the Swiss 

laboratory Spirig, the dermatology 

market leader in Switzerland. In 2012, 

for the first time in the history of 

Galderma, more than half of sales were 

generated outside the United States: the 

company has truly become international. 

Galderma is more conscious than 

ever of its increased responsibilities towards 

patients and stakeholders, and of 

the importance of driving a business 

with compliance and respect. 

(1) Source: IMS data - D+J1A+J2A (dermatology 

only), MAT December 2012 – 39 countries. 


all countries selected - Topical anti acne market - 

Nov.2012 MAT, retail Rx Market - at sales manufacturer 

local currency dollar value. 

x2 over 120% 

THE COMPANY’S GROWTH IN CHINA IN 2012. 

THE NUMBER OF EMPLOYEES 

IN THE ASIA PACIFIC REGION 

MORE THAN DOUBLED IN 2012. 

CHINA IS SET TO BECOME THE WORLD’S 2ND 

PHARMACEUTICALS MARKET IN THE NEXT 5 YEARS. 

Source: Company data, at the end of 2012, at comparable rates. 

Transformation and 

reinforcement in the US 

With about 600 employees, 

Galderma’s number one market 

continues to expand, generating sales 

of around $1 billion. The company 

made news in the US in 2012 with four 

product launches (Epiduo, Metrogel, 

Differin 0.3% pumps and Cetaphil 

Dermacontrol for acne-prone skin), 

two registrations and ten FDA 

consultations while championing 

compliance and safety. A leader in the 

US Prescription market, Galderma’s 

brand growth and performance has 

surpassed demand with Clobex Spray, 

Epiduo and Oracea. The Selfmedication 

category was also 

reinforced thanks to the continued 

strength of flagship brand Cetaphil 

– one product is sold every second - 

and the successful launch of Cetaphil 

Dermacontrol among the dermatology 

and pediatric community. 

The supplement approved by 

the FDA for Pliaglis, a topical 

anesthetic as well as the comeback 

of Tri-Luma, treating pigmentary 

disorders marked new steps 

reinforcing Galderma’s presence 

in the Aesthetic & Corrective area. 

Galderma’s dedicated Managed Care 

team promotes quality healthcare for 

dermatology patients by partnering 

with managed care organizations, 

insurers and third-party payers. 

The company actively supports 

dermatologic and pediatric 

organizations via direct, unrestricted 

grants and donations amounting to 

$20 million in the last five years. Last 

but not least, US-based dermatologists 

have recognized Galderma as the No.1 

dermatological company for seven 

consecutive years (3) . 

(3) SDI Company Image Survey — Results 

in Dermatology, 2011. 

Brazil: 

Three-category leader 

Brazil is a standout example of how 

Galderma shapes local markets 

by responding to local needs with 

a complete portfolio and three 

businesses at play. In the Prescription 

market, Epiduo consolidated its 

leadership as the first topical acne 

treatment. The third “Acne Day” 

in São Paulo was a success, with 

700 physicians attending. Clobex, 

Avicis and Loceryl significantly gained 

market share. The Self-medication 

products lead in four of the six market 

segments where they are present, 

taking the leadership for the first time 

in the moisturizer market with 22.4% 

market share, thanks to the support of 

a dedicated sales team covering 3,000 

pharmacies. Aquaclin was launched as 

the first OTC brand for acne treatment. 

As part of Galderma’s scientific 

studies support, the first Brazilian 

epidemiological study in 

onychomycosis “ONO” was 

presented. In Aesthetic & Corrective, 

Dysport is the leading brand on 

the botulinum toxin dermatology 

market, with 54% of market share. 

Restylane reached record sales 

of 100,000 units. The symposium 

addressing the global approach 

of facial anatomy and treatment 

with Dysport and Restylane drew 

3,500 participants during the National 

Brazilian Congress. The Alliance 

service platform in the aesthetic 

area was launched adding significant 

value to the brands with 

a cluster management model. 

These results were possible due to 

a complete professional relationship 

program. Among many other 

initiatives, the ‘Fellowship Program’ 

reached 600 fellows, supporting 

various scientific projects and 

initiatives. 

Sources: IMS, CUP, SAFE System, Research 

- A&C Census. 

50 

51

INTERNATIONAL 

Galderma worldwide 

PARIS 

FRANCE 

CORPORATE SERVICES 

UPPSALA 

SWEDEN 

R&D AND PRODUCTION 

ASIA-PACIFIC 

AUSTRALIA 

CHINA 

HONG KONG 

INDIA 

JAPAN 

PHILIPPINES 

SOUTH KOREA 

SINGAPORE 

TAIWAN 

FORT WORTH 

TEXAS, USA 

NORTH AMERICA 

HEADQUARTERS 

GALDERMA IS 

EXPANDING ITS 

INTERNATIONAL 

PRESENCE, COVERING 

MORE THAN 70 

COUNTRIES TODAY. 

BAIE D'URFÉ 

CANADA 

PRODUCTION 

PRINCETON 

NEW JERSEY, USA 

R&D 

SOPHIA ANTIPOLIS 

FRANCE 

R&D 

ALBY-SUR-CHÉRAN 

FRANCE 

PRODUCTION 

LAUSANNE 

SWITZERLAND 

GLOBAL HEADQUARTERS 

TOKYO 

JAPAN 

R&D 

EUROPE - MIDDLE EAST 

AFRICA 

BELGIUM 

FRANCE 

GERMANY 

GREECE 

ITALY 

POLAND 

PORTUGAL 

RUSSIA 

SOUTH AFRICA 

SPAIN 

SWEDEN 

SWITZERLAND 

THE NETHERLANDS 

UNITED KINGDOM 

LATIN AMERICA 

ARGENTINA 

BRAZIL 

CHILE 

COLOMBIA 

MEXICO 

VENEZUELA 

NORTH AMERICA 

CANADA 

UNITED STATES OF AMERICA 

With 31 affiliates and exclusive representatives 

throughout the world, 

Galderma is developing markets 

in high potential regions while 

answering global needs in its three 

businesses: Prescription, Self-medication 

and Aesthetic & Corrective 

medical solutions. 

FIND ALL GALDERMA OFFICES 

AROUND THE WORLD 

ON WWW.GALDERMA.COM 

HORTOLÂNDIA 

BRAZIL 

PRODUCTION 

52 

53

Key brands 

Galderma locations 

VISIT ALL THE AFFILIATES WEBSITES ON WWW.GALDERMA.COM 

HEADQUARTERS 

SWITZERLAND 

GALDERMA SA 

Avenue Gratta-Paille 2 

1018 LAUSANNE 

Tel.: 41 21 642 78 00 

CORPORATE SERVICES 

FRANCE 

GALDERMA 

INTERNATIONAL S.A.S. 

Tour Europlaza La Défense 4 

20 avenue André Prothin 

92927 La Défense Cedex 

Tel.: 33 1 58 86 45 45 

SWITZERLAND 

GALDERMA SA 

Avenue Gratta-Paille 2 

1018 LAUSANNE 

Tel.: 41 21 642 78 00 

R&D 

FRANCE 

GALDERMA R&D S.N.C. 

Les Templiers 

2400, route des Colles 

06410 Biot 

Tel.: 33 4 93 95 70 70 

JAPAN 

GALDERMA KK (Japan) 

9th Floor, Sumitomo Fudosan 

Iidabashi No.3 Building 

13-1 Nishi-Gokencho 

Shinjuku-ku 

Tokyo 162-0812 

Tel.: 81 3 5229 6900 

SWEDEN 

Q-MED AB 

Seminariegatan 21 

Visitors: Fyrisvallsgatan 7 

752 28 Uppsala 

Tel.: 46 18 474 90 00 

UNITED STATES 

GALDERMA R&D LLC 

5 Cedar Brook Drive - Suite 1 

Cranbury, NJ 08512 

Tel.: 1 609 409 77 01 

PRODUCTION SITES 

BRAZIL 

GALDERMA BRASIL Ltda. 

Rodovia SP 101 

Campinas-Monte Mor, Km 9 

Condominio Techtown 

CEP 13186-904 

Hortolândia-SP 

Tel.: 55 19 3045 6900 

CANADA 

GALDERMA PRODUCTION 

CANADA INC 

19400 Trans-Canada Hwy 

Baie d'Urfé, Québec H9X 3S4 

TEL.: 1 514 457 33 66 

FRANCE 

LABORATOIRES 

GALDERMA S.A.S. 

Zone Industrielle - Touvière 

74540 Alby sur Chéran 

Tel.: 33 1 58 86 45 45 

SWEDEN 

Q-MED AB 


Visitors: Fyrisvallsgatan 7 


Tel.: 46 18 474 90 00 

AFFILIATES 

ARGENTINA 

GALDERMA ARGENTINA S.A. 

Juramento 1775 8° Piso 

(C1428DNA) 

Ciudad de Buenos Aires 

Tel.: 54 11 4124 0454 

AUSTRALIA / NEW ZEALAND 

GALDERMA AUSTRALIA 

(PTY) LTD. 

Suite 4, 13B Narabang Way 

Belrose NSW 2085 

Tel.: 61 2 9479 0600 

BELGIUM 

GALDERMA BELGILUX BN 

p/a Multiburo 

Keivitplein 20C/12 

2018 Antwerpen 

Tel.: 32 3 897 19 00 

BRAZIL 

GALDERMA BRASIL LTDA. 

R. Surubim, 373 - 4th floor 

Cid. Monções - São Paulo / 

SP 04571-050 

Tel.: 55 11 3524 6300 

CANADA 

GALDERMA CANADA INC. 

105 Commerce Valley Drive 

West - Suite 300 

Thornhill, Ontario L3T 7W3 

Tel.: 1 905 762 2500 

CHILE 

LABORATORIOS GALDERMA 

CHILE LTDA. 

Mc Iver N 440 - 

Office N 701 

Santiago Centro 

Tel.: 56 2480 7500 

CHINA 

GALDERMA INTERNATIONAL 

3708 Lippo Plaza 

No. 222 Middle Huaihai Rd. 

Shanghai 200021 - P.R.China 

Tel.: 86 21 2315 9666 

COLOMBIA 

GALDERMA COLOMBIA S.A. 

Carrera 14 N93 B-32 

Oficina 504 - Bogota, DC 

Tel.: 57 1622 7560 ext 201 

FRANCE 

GALDERMA 

INTERNATIONAL SAS 

Tour Europlaza - La Défense 4 

20, Avenue André Prothin 

92927 La Défense Cedex 

Tel.: 33 1 5 8 86 45 45 

GERMANY 

GALDERMA LABORATORIUM 

GMBH 

Georg-Glock-Strasse 8 

40474 Düsseldorf 

Tel.: 49 211 58 601 00 

GREECE 

GALDERMA HELLAS TRADE 

OF PHARMACEUTICAL 

PRODUCTS S.A. 

Pendelis Avenue 37A 

15235 Vrilissia Attica 

Tel.: 30 210 81 04 190 

HONG KONG 

GALDERMA HONG KONG LTD. 

Suite 3501-02, 35/F, 

Cambridge House, Taikoo 

Place, 979 King's Road 

Island East, Hong Kong 

Tel.: 852 28240333 

INDIA 

GALDERMA INDIA PVT. LTD. 

23, Steelmade Industrial Estate, 

2nd Floor - Marol Village, 

Andheri (E) - Mumbai 400 059 

Tel.: 91 22 6726 1818 

ITALY 

GALDERMA ITALIA S.p.A. 

Centro Direzionale Colleoni 

Palazzo Taurus - Ingresso 1 

20864 Agrate Brianza (MB) 

Tel.: 39 039 63 46 91 

JAPAN 

GALDERMA KK (Japan) 

9th Floor, Sumitomo Fudosan 

Iidabashi No.3 Building 

13-1 Nishi-Gokencho 

Shinjyuku-ku 

Tokyo 162-0812 

Tel.: 81 3 5229 6900 

MEXICO 

GALDERMA MEXICO S.A. 

de CV Mariano Escobedo 

N°. 476 - Piso 10, Torre Polanco 

Col. Anzures 

Delegación Miguel Hidalgo 

11590 México, D.F. 

Tel.: 52 55 9126 2000 

PHILIPPINES 

GALDERMA 

PHILIPPINES INC. 

Unit 3001 Atlanta Centre 

31 Annapolis Street 

Greenhills, San Juan 

Metro Manila 1502 

Tel.: 63 2 470 8000 

POLAND 

GALDERMA POLSKA Sp.z.o.o. 

ul. Laczyny 4 

02-820 Warsaw 

Tel.: 48 22 331 21 80 

PORTUGAL 

GALDERMA INTERNATIONAL 

Sucursal em Portugal 

R. Dr. Antonio Loureiro 

- Borges, n7 - 6 Andar - 

Arquiparque - Miraflores 

1495 - 131 Alges 

Tel.: 351 21 315 19 40/41 

RUSSIA 

GALDERMA LLC. 

Leningradskiy prospect 31A, 

building 1 - Business Center 

Monarkh Tower - 21st floor 

125284, Moscow 

Tel.: 7 495 540 5017 

SINGAPORE 

GALDERMA SINGAPORE 

PVT. LTD. 

1 Kim Seng Promenade 

#14-10, Great World City West 

Tower - Singapore 237994 

Tel.: 65 6838 9360 

SOUTH AFRICA 

GALDERMA LABORATORIES 

SOUTH AFRICA (PTY) LTD. 

Wedgefield Office Park 

17 Muswell Road South 

Bryanston - Phase 2, Block 

D, 1st Floor - P.O. Box 71150 - 

Bryanston 2021 

Tel.: 27 11 706 23 39 

SOUTH KOREA 

GALDERMA KOREA Ltd. 

6F, 7F Bando Building 

26 Gromurae-Ro 10-Gil 

Seocho-Gu, Seoul, 137-802 

Tel.: 82 2 6717 2000 

SPAIN 

LABORATORIOS 

GALDERMA S.A. 

C/ Agustín de Foxá, 29 - 4 Pl. 

28036 Madrid 

Tel.: 34 902 02 7595 

SWEDEN 

GALDERMA NORDIC AB 



Tel.: 46 18 444 0330 

SWITZERLAND 

GALDERMA S.A. 

Postfach 492 - 6330 Cham 

Tel.: 41 41 7803828 

TAIWAN 

GALDERMA HK LTD 

Taiwan Branch 

4-6, 9F, N° 17, Sec. 1 

Chengde Rd., Datong Dist. 

Taipei City 103 

Tel.: 886 22 555 8850 

THE NETHERLANDS 

GALDERMA BENELUX BV 

Postbus 2892 - 

3000 CW Rotterdam 

Visitors: Weena 723 C7.082 

Rotterdam 

Tel.: 31 183 69 19 19 

UNITED KINGDOM 

GALDERMA (UK) LTD. 

Meridien House, 1st Floor 

69 - 71 Clarendon Road 

Watford, Hertfordshire 

WD17 1DS 

Tel.: 44 1923 208 950 

UNITED STATES 

GALDERMA 

LABORATORIES L.P. 

14501 North Freeway 

Fort Worth, TX 76177 

Tel.: 1 817 961 5000 

VENEZUELA 

LABORATORIOS GALDERMA 

VENEZUELA S.A. 

Urbanizacion Sorocaima 

Calle Altagracia 

Edificio Procter & Gamble, 

Nivel Plaza, Mezzanina Sector 

La Trinidad - ZP 1080, 

Caracas - Edo. Miranda 

Tel.: 58 212 820 83 80 

54

Yearbook 2012 - Galderma

Create successful ePaper yourself

Delete template?

Save as template?